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Abstract.
The anti-proliferative function o f the p53 tumour suppressor depends primarily on 
its ability to act as a transcription factor and to coordinate the cellular response to 
various stress signals. p53 can induce several cellular responses, including cell- 
cycle arrest, DNA repair and apoptosis. The choice o f the p53 response is thought 
to depend on many factors, including the action o f p53-cooperating molecules.
The cofactor JMY has been demonstrated to cooperate with the p300 coactivator 
to augment p53 activity. The aim o f this study was to investigate the mechanisms 
regulating JMY function to further understand its role in the stress response. 
Results presented here indicate that the subcellular localisation o f JMY is 
regulated by the cellular environment. Whilst DNA damage stimulated the 
translocation o f JMY from the cytoplasm to the nucleus, removal o f proliferative 
and survival signals by serum deprivation induced rapid nuclear export o f JMY 
and compromised its ability to affect cell cycle progression and stimulate 
apoptosis.
The Mdm2 oncoprotein negatively regulates p53 activity at multiple levels 
including regulation of the intracellular location o f p53 and inliibition o f its 
interaction with the transcriptional coactivator CBP. Mdni2 interacts with JMY in 
cells, and enhances its cytoplasmic localisation without promoting its degi'adation. 
Leptomycin B blocked Mdm2-dependent redistribution o f JMY, implying the 
involvement o f a nuclear export mechanism. DNA damage was found to abrogate 
the effect o f Mdm2 on the subcellular localisation of JMY, and to reduce the
interaction between the two proteins. Mutations in the ubiquitin ligase domain of 
Mdm2, as well as removal o f the proline-rich region in JMY abolished the Mdm2- 
mediated cytoplasmic translocation o f JMY. These data suggest the existence of 
a functional relationship between the p53 cofactor JMY, and its major inhibitor 
Mdm2, which is likely to impact on p53 activity. Importantly, regulation o f the 
intracellular localisation o f JMY might provide an additional mechanism of 
modulating the p53 response.
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Chapter 1. Introduction
Although cancer research and the study o f evolution seem to be very distant 
branches o f biological study, they focus on similar fundamental mechanisms. 
Cancer can be viewed as an evolutionary process at a micro-scale, not at the level 
o f populations or whole organisms but at the cellular level. In fact, the two major 
forces o f evolution, mutation and selection are also the driving forces in the 
development of cancer.
Cancer is a disease characterised by the progressive accumulation of genetic 
alterations which eventually lead to the transformation o f noimal cells to 
malignant cells with increasingly aggressive gi'owth properties. Such cells must 
evade the cellular defence mechanisms that normally protect against malignancy, 
and this process is accelerated by lesions that target the cellulai* machinery 
involved in the control o f cellular proliferation, and the maintenance o f genomic 
integrity.
Human cancer mutations target two major classes o f genes, the “caretaker” genes 
involved in the repair o f DNA lesions, and the growth controlling oncogenes and 
tumour suppressor genes (Kinzler and Vogelstein, 1997).
Since tumour suppressor proteins act to restrain cellular growth, their inactivation 
confers a growth advantage to tumour cells and is a critical factor in 
tumourigenesis. In particular, the p53 protein, which possesses potent tumour 
suppressor functions, is targeted in the majority o f human cancers. This resulted 
in the protein being the focus o f intensive research that aims to understand its
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function and dysfunction and to use the acquired knowledge in the development 
o f novel cancer therapies.
1-1. Regulation of the p53 tumour suppressor protein
The p53 tumour suppressor is a short lived transcription factor with a pivotal role 
in the prevention o f malignant disease. The function o f the protein is tightly 
regulated by an intricate web o f regulatory mechanisms which ensure its 
appropriate activation, and coordinated action in response to a variety o f cellular 
insults. The ability o f p53 to suppress tumourigenesis is mediated through its 
ability to cause cell cycle arrest, programmed cell death or DNA repair in 
response to cellular stress.
Mutation o f the p53 tumour suppressor is one o f the most common aberrations 
observed in tumours. It is estimated that at least 50% o f human cancers cany 
mutations o f the p53  gene (Hollstein et a l ,  1994), and accumulating evidence 
indicates that a large part o f the remaining cancers bear mutations that target 
downstream or upstream effectors of the p53 pathway (Vousden and Lu, 2002). 
The most common mutations identified in the p53  gene are missense mutations 
affecting one allele, and causing the production o f a mutant protein that 
accumulates at high levels in cells. The remaining wild type allele is often 
mutated or lost later during tumourigenesis. Rare deletions or chain tenninations 
o f the p53  gene have also been obseiwed and cause a cancer-predisposing p53  null 
phenotype (Levine, 1997).
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Moreover, p53 is frequently targeted by virally encoded oncoproteins such as 
SV40 large T antigen, adenovirus E l A, and HPV E6, which inactivate its 
function (Prives and Hall, 1999).
The importance o f p53 in the development o f cancer is also highlighted by the 
phenotype o f p53  null mice. These mice develop normally but display a very 
high susceptibility to cancer (Donehower et al., 1992). Furthermore, germline 
mutations o f p53 are associated with the cancer-predisposition Li-Fraumeni 
syndrome. Affected individuals develop a wide variety o f tumours often at a very 
early age (Malkin et ah, 1990).
1-1.1 Integration of cellular insults at p53
p53 is kept at low levels, in a latent form imder normal conditions. However, a 
number o f cellular stresses result in rapid stabilisation and activation o f the 
transcription factor, which then mediates the cell response to the particular stress 
signal (Levine 1997) (figure 1.1).
Several types o f stress have been shown to induce p53 activity, including DNA 
damage in the form o f double strand breaks as well as DNA repair intermediates 
resulting from ultraviolet exposure and chemical damage to DNA (Levine, 1997). 
In addition to DNA damage, hypoxia is able to stimulate p53 activity (Graeber et 
a l,  1996). This is relevant to the biology o f tumours as hypoxia occurs when 
tumours reach a critical size when the blood supply becomes rate-limiting. At this 
stage, tumour cell survival and continued growth depends on the formation o f new 
blood vessels, a process termed angiogenesis. Activation o f p53 by hypoxia will
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eliminate such cells, and may also be involved in the prevention o f angiogenesis, 
as suggested by its ability to regulate the gene encoding the anti-angiogenic factor 
thrombospondin (Dameron et aL, 1994).
Moreover, p53 is activated when the levels o f  ribonucleoside triphosphate, which 
are required to support DNA replication and repair, are low (Linke et al., 1996). 
It also responds to aberrant gi'owth signals such as those emanating from 
abnormal activation o f oncogenes, including Ras and Myc. The oncogenic 
pathway o f p53 activation involves the function o f another tumour suppressor, 
ARF (SheiT and Weber, 2000).
1-1.2 The downstream effects of p53
Activation o f p53 results in multiple cellular responses that are not only 
detennined by the type and intensity o f cellular stress, but also by the genetic and 
enviromnental context o f the cell. The p53 response can manifest in the form o f 
DNA repair, senescence and regulation o f angiogenesis but the best understood 
activities o f p53 are those that inliibit cell giowth through cell cycle arrest and 
apoptosis (figure 1.1).
Cell cycle arrest
The ability o f  p53 to induce cell cycle amest is conelated with its function as a 
transcription factor. A transcriptional target o f p53 that is critical for this function 
is the gene (El Deiry et a l,  1993). The gene product is a cyclin
dependent kinase inliibitor which can block the cell cycle at both the G1 and G2
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phases. Further, p21 binds to the DNA polymerase processivity factor PCNA 
(proliferating cell miclear mitigen), and blocks its function in DNA replication but 
not its DNA repair function. Loss o f p21 impairs G1 and G2 arrest and results in 
uncoupling o f DNA synthesis and mitosis (Waldman et al., 1995).
Gadd45, the product o f another p 53-responsive gene, can also cause G1 arrest in 
certain cells in culture. Gadd45 also interacts with PCNA and this interaction is 
also implicated in DNA repair (Smith et al., 1994).
The cell cycle anest functions o f p53 also extend to the G2/M checkpoint. 
Members of the 14-3-3 family o f proteins are involved in signal transduction and 
cell cycle control, and can mediate their effects by binding and sequestering 
proteins (Muslin and Xing, 2000). 14-3-3 sigma is induced by p53 and appears to 
mediate the role o f p53 at the G2/M checkpoint (Henneking et al., 1997). 14-3-3 
sigma deficient cells can still arrest at G2 but are unable to maintain this arrest 
(Chan et al., 1999). Other p53 induced proteins which can contribute to G2 arrest 
include Gadd45 (Wang et al, 1999), and Reprimo (Oliki et al., 2000). Moreover, 
p53 may contribute to G2/M aiTest by negatively regulating the cellular levels o f 
cyclin B l, which is required for the initiation o f mitosis (Innocente et al.,1999).
Apoptosis
In addition to transient cell cycle arrest, p53 can irreversibly block cell growth by 
inducing programmed cell death through several apoptotic pathways. Both 
transcription dependent and independent mechanisms are believed to contribute to
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p53-induced apoptosis, and the importance of p53-mediated transcription in this 
process has been controversial.
p53-dependent apoptosis was reported in experimental systems in the presence o f 
actinomycin D, which blocks RNA synthesis, and cycloheximide, which prevents 
protein synthesis. In these systems, transcriptional activation or translation o f 
p53-regulated genes is prevented and camiot account for the observed apoptotic 
cell death (Gaelics et aL, 1994). In addition, introduction o f p53 transcriptional 
activation mutants into cells induced apoptosis, albeit more slowly than the wild 
type protein (Haupt et aL, 1995).
Another line o f evidence that questions the requirement for p53 transactivation for 
apoptosis comes fi'om examination o f the effect o f Rb on the stability and activity 
o f p53. The interaction o f p53 with its negative regulator Mdm2 blocks its 
transactivation, cell cycle aiTest and apoptotic activities and promotes its nuclear 
export and degradation (Vousden, 2002). Rb fonns a trimeric complex with p53 
and Mdm2, blocking Mdm2-dependent p53 degradation. This restores the 
apoptotic activity o f p53 as well as its ability to repress transcription. However,
Rb binding does not relieve Mdm2/s inhibition o f p53 transactivation (Hsieh et H
aL, 1999). Taken together, these data demonstrate that p53 dependent gene 
activation is not essential for the induction o f apoptosis.
Nevertheless, this conclusion was challenged by a study in whieh homologous 
recombination was used to generate mice carrying a transactivation-defective p53 
mutant (Jimenez et aL, 2000). Analysis o f mouse embryo fibroblasts (MEFs)
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from these mice revealed defects in cell cycle regulation and apoptosis and the 
cells were readily transformed by oncogenes. These data firmly establish the 
transactivation function o f p53 as a cmcial determinant o f its apoptotic activity 
(Jimenez et ah, 2000).
Consistent with the trans activation function o f p53 being necessary for the 
effective induction o f apoptosis is the ability o f p53 to activate genes involved in 
programmed cell death. Many o f these encode proteins that mediate apoptosis via 
the mitochondrial pathway, the death receptor pathway, and there is evidence for 
inhibition of survival signalling by some o f these gene products.
The mitochondrial pathway
One o f the first p53 responsive genes to be involved in apoptosis is the bax gene 
(Miyashita and Reed, 1995), which encodes a Bcl-2 -fam ily  member. Apoptotic 
stimuli promote the translocation o f Bax from the cytoplasm into the 
mitochondria, where it mediates cytochi'ome C release. p53 also activates the 
expression o f PegS/Pwl which encodes a protein that triggers Bax translocation to 
the mitochondria, an effect blocked by expression o f Peg3/Pwl antisense (Deng 
and Wu, 2000).
Other proteins involved in the mitochondrial pathway that are encoded by p53 
responsive genes include NOXA, PUMA and A IPl which contribute to the loss of 
mitochondrial membrane potential, triggering cytoclii'ome C release (Oda, E. et 
aL, 2000; Oda et al, 2000; Nakano et aL, 2001; Yu et aL, 2001). Further down
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the same pathway, the interaction o f cytoclirome C with the p53-inducible Apafl 
triggers the caspase degradation pathway thus committing the cells to apoptosis 
(Srinivasula e ta l ,  1998).
Another mechanism by which p53 activation targets the mitochondria involves 
PIGS, j?53 mducible genes whose activation is associated with the generation of 
reactive oxygen species (ROSs). ROSs can cause damage to the mitochondria, 
which triggers apoptosis (Polyak et aL, 1997).
Furthermore, a transcription-independent role o f p53 at the mitochondria has 
recently been proposed. p53 has been reported to localise at the mitochondria of 
tumour cells undergoing p53-mediated apoptosis, but not in cells undergoing p53- 
dependent anest or p53-independent apoptosis (Marchenko et aL, 2000). 
Moreover, the mitochondrial localisation o f p53 was correlated with its apoptotic 
activity (Dumont et aL, 2003). Another study showed the ability o f p53 to 
localise to the mitochondria o f ionising radiation-treated lymphocytes (Mihara et 
al, 2003), and to antagonise the function of the anti-apoptotic molecules Bcl-2 and 
Bcl-xL in a transactivation-independent fashion (Mihara et al, 2003).
Death receptor/death domain pathway
p53 may be involved in death receptor-mediated cell death. It activates the 
expression o f genes encoding the death receptors DR5/KILLER and FAS/APOl 
(Takimoto and El Deiry, 2000, Fuchs et aL, 1997, Bennet et aL, 1998).
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PIDD {pS3 induced jcrotein with a rieath riomain), is another p53-induced pro- 
apoptotic protein. PIDD as been proposed as a mediator o f apoptosis as anti-sense 
inhibition o f PIDD reduces apoptosis in response to p53 activation and DNA 
damage (Lin et aL, 2000).
Loss o f  survival sisnallins'.
In addition to apoptotic signals, cell death can also be potentiated by inliibition of 
survival and anti-apoptotic signals. The IGF BP3 gene product blocks the 
interaction o f IG Fl with its receptor, thus blocking the IGF mitotic signalling 
pathway (Buckbinder et aL, 1995). Similarly, the tumour suppressor PTEN blocks 
survival signals associated with PI3K7Akt signalling and contributes to the 
stabilisation o f p53, thus promoting its growth inhibitory function (Mayo et a l,  
2002).
1-1.3 Choice of response to p53
The outcome o f p53 activation appears to be determined by a multitude o f factors. 
Understanding these factors would provide important tools in the development o f 
p53-based cancer therapies. As p53 is a stress responsive protein, it makes sense 
that the type and intensity o f stress dictate the outcome o f the response. 
Furthermore, tumourigenesis is associated with the accumulation o f multiple 
cellular abeiTations and with increased genomic instability. The extent o f these 
aberrations could affect the way in which the cell responds to p53 activation 
(Vousden and Lu, 2002).
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Other factors affecting the outcome o f the p53 response include differential 
binding affinities for p53 apoptotic and cell cycle airest genes. Apoptotic genes 
are thought to have a lower affinity for p53 binding, which m ay explain the 
correlation o f apoptosis with high levels o f p53 and cell cycle an*est with lower 
concentrations of the protein in certain experimental systems (Chen et aL, 1996). 
However, despite differences in binding affinity between certain p53-responsive 
promoters, the finding that the PUMA promoter is not different hom  the p21 and 
mdm2 gene promoters with respect to p53 binding indicates that binding affinity is 
not the sole factor affecting the choice o f p53 response (ICaeser et aL, 2002).
Phosphorylation o f p53 can contribute to promoter specificity as is exemplified 
by the A IP l gene promoter. Phosphorylation o f p53 at serine 46 is required for 
activation o f the gene, which encodes a pro-apoptotic molecule (Oda et aL, 2000).
Moreover, accumulating evidence implicates p53 cooperating proteins in the 
induction o f apoptosis. The p53 homologues p63 and p73 may perfonn such 
functions since p53 is unable to bind promoters of apoptotic genes in p63/p73  
double null cells, and is compromised in its ability to induce apoptosis (Flores et 
aL, 2002).
Other p53 cooperating molecules that modulate the choice o f p53 response 
include ASPP family members, which affect p53)^s ability to bind to responsive |
promoters. A SPPl and 2 bind to p53, enhancing its interaction with promoters o f 
apoptotic genes such as bax. ASPP proteins greatly stimulate p53-dependent
25
apoptosis and their inliibition blocks the apoptotic activity o f p53 (Samuels-Lev 
et a l ,  2001).
Similarly, the p300 cofactor JMY augments p53 dependent apoptosis by 
selectively enliancing p53’s ability to activate apoptotic genes such as bax 
(Shikama a/., 1999).
Interestingly, alternative splicing o f the JMY inRNA results in a protein isoform 
JMYAP, which favours p53-dependent G1 arrest as opposed to apoptosis 
(Shikama et al., 1999). Thus, it is an attractive speculation that expression o f the 
different isoforms o f JMY, potentially in response to different fonns o f stress, can 
direct the p53 response towards G1 anest, apoptosis, or possibly favour other p53- 
mediated reponses.
1-1.4 Regulation of p53 function
As described above, p53 activation triggers potent growth inhibitory processes 
which would be detrimental to normal cells. This is demonstrated by the adverse 
side effects o f chemotherapeutic agents which are believed to be at least partly 
due to p53 (Komarov et aL, 1999). Moreover, loss o f Mdm2-dependent 
regulation o f p53 in mdm2'^' mice has a lethal phenotype that is attributed to 
excessive p53-dependent cell death (Jones et aL, 1995). Therefore, p53 activity 
must be kept in check during nonnal growth and development. Various cellular 
processes feed into the p53 pathway, providing tight regulation o f the tumour 
suppressor, and inducing its activity when necessaiy. p53 regulation has been 
described at the level of its transeription and translation but most importantly at
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the level o f its stability, its sub cellular localisation and its activity as a 
transcription factor.
Resulation o f  v53 stability
In addition to genes involved in cell cycle arrest and apoptosis, p53 activates the 
expression o f genes involved in its own regulation. The most important o f these 
is probably the mdm2 gene. The Mdm2 protein is recognised as one o f the major 
regulators o f p53 and mediates its function by promoting the ubiquitination o f 
p53, which allows its recognition and degradation by the 26S proteasome (Haupt 
et aL, 1997, Kubbutat et aL, 1997, Fang et aL, 2000). The resulting feedback 
loop, in which p53 induces the expression o f its own negative regulator, is 
responsible for maintaining low levels o f the tumour suppressor and needs to be 
intemapted to allow p53 accumulation in response to cellular stress.
p53 phosphorylation has been linked to its ability to stabilise in response to 
various forms o f stress. Several potential phosphorylation sites have been 
identified in both the N-temiinus and C-tenninus o f p53 including serines 15, 
20,33, 37 and 46 and threonine 18 and 81 (Buschmann et aL, 2001 and references 
within). Phosphorylation o f some o f these residues has been correlated with 
increased stability o f p53 and attenuated interaction with Mdm2. Examples 
include phosphorylation o f Serine 15 by the ATM (ritaxia telangiectasia mutated) 
kinase, and serine 20 by the Clilc2 kinase (Chehab et aL, 2000). The importance 
o f the ATM/Chle kinase cascade in activating the p53 response to certain types o f 
genotoxic damage is highlighted by the finding that Clik2 deficient cells are
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defective in their ability to stabilise p53 in response to ionising radiation (Hirao et 
aL, 2000).
Further evidence for the role o f phosphorylation in regulating p53 stability comes 
from mouse embryonic stem cells in which serine 18 (equivalent to human serine 
15) was mutated (Chao et aL, 2000). The p53 mutant accumulates less efficiently 
compared to wild type p53 and is compromised in its ability to induce p21 gene 
expression and cell cycle arrest (Chao et aL, 2000).
Nevertheless, the requirement for phosphorylation in p53 stabilisation has been 
questioned by studies o f mutants in which all potential N-terminal 
phosphorylation residues were altered into non phosphorylatable residues 
(Ashcroft et al, 1999; Blattner et aL, 1999). These mutants are stabilised in a 
comparable fashion to the wild type protein indicating that phosphorylation is not 
essential for p53 stabilisation.
The ability o f p53 to accumulate in the absence o f phosphorylation suggests that 
other mechanisms are involved in its stability. Since Mdm2 is a major regulator 
o f p53 stability, regulation o f Mdm2 activity is likely to be one such mechanism, 
and can occur at the level o f its transcription, protein levels as well as by 
postranslational modification (described below).
In addition to Mdm2, other proteins that target p53 for degradation include the Jun 
NH2 terminal kinase, INK. INK binding to p53 promotes its ubiquitination and
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subsequent proteolysis (Fuchs et aL, 1998). JNK can also phosphorylate p53 at 
threonine 81, leading to its stabilisation and entranced growth arrest and apoptosis 
by p53 (Busclimann et aL, 2001), providing another example o f the positive effect 
o f p53 phosphorylation on its protein levels.
p53 phosphorylation does not always con*elate with accumulation o f the protein. 
Phosphorylation o f tlrreonine 155 by the C 0P9 signalosome enhances its 
degradation (Bech-Otschir et aL, 2001) and may contribute to maintaining low 
levels o f p53 in the absence o f stress. Similarly, protein kinase C-dependent 
phosphorylation o f p53 in the C-terminus also enhances its ubiquitination and 
degradation in unstressed cells (Chernov et aL, 2001).
Resulation o f  the subcellular localisation o f  u53
As discussed above, the ability to act as transcription factor is important for p53/s 
growth inlribitory function. Since transactivation is a nuclear process, the nuclear 
localisation o f p53 is cmcial for its function and, like every aspect o f p53 
function, is subject to regulation.
Three nuclear localisation signals (NTS) have been identified in the C-terminal 
domain o f p53 (figure 1.1.B), the first o f which appears to be the most active in
mediating p53 nuclear import (Liang et aL, 1999). The C-terminus o f p53 also
contains a cytoplasmic sequestration domain (CSD) that can reduce the efficiency 
o f p53 nuclear import (Liang et aL, 1998,1999), and a nuclear export signal (NES) 
that allows leptomycin B sensitive p53 export (Stommel et aL, 1999). Another
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NES sequence has more recently been identified in the N-terminal transcativation 
domain o f p53 (Zhang and Xiong, 2001).
The N-terminal leucine rich NES o f p53 has been implicated in stress-regulated 
control o f p53 localisation. DNA damage-induced phosphorylation within this 
domain (serine 15) blocks export o f p53 and may contribute to the nuclear 
accumulation o f the protein in the presence o f stress (Zhang and Xiong, 2001). 
Thus, in addition to contributing to the stability o f p53, phosphorylation can also 
regulate its localisation within the cell.
The C-terminal localisation signals are close to, and in the case o f the NES, 
contained within the oligomerisation domain o f p53. Mutations in the C-tenninal 
NES were reported to affect nuclear export as well as tetramer foimation which 
suggested a possible role for tetramerisation in the regulation o f p53 localisation 
(Stommel et aL, 1999). This hypothesis was supported by studies in 
neuroblastoma cells in which p53 localises mainly to the cytoplasm as a result o f 
enhanced nuclear export (Moll et aL, 1995; Stommel et aL, 1999). Ectopic 
expression of the tetramerisation domain restores the nuclear localisation o f p53, 
implying that tetramerisation can mask the NES, and block p53 nuclear export 
(Stommel et aL, 1999).
The Mdm2 protein is a major regulator o f p53 function and it has been shown to 
affect p53 localisation. The ring finger domain o f Hdm2, which harbours its 
ubiquitin ligase activity, is essential for it ability to relocalise p53 to the cytoplasm
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(Boyd et al, 2000, Geyer et al., 2000). Moreover, ubiquitination-deficient p53 
mutants are resistant to Mdm2-mediated nuclear export (Lolmim et al.,200\). 
Taken together, these data suggest that ubiquitination o f p53 can affect its 
cellular loealisation and enliance its export.
In addition to nuclear export mechanisms, cytoplasmic sequestration o f p53 has 
also been proposed to affect its intracellular localisation. Interaction o f p53 with 
the glucocorticoid receptor (GR) results in the cytoplasmic sequestration o f p53 
and this is accompanied by inactivation o f p53’s transactivation and growth 
inhibitory frinctions (Sengupta et al., 2000). In neuroblastoma cells, where p53 
localises mainly to the cytoplasm, disruption o f the p53-GR complex with GR 
antagonists restores the nuclear localisation o f p53 as well as its ability to activate 
transcription, and to promote growth an'est and apoptosis (Sengupta et aL, 2000).
Another molecule that can retain p53 in the cytoplasm is Parc (p53-associated 
parkin-like protein). Parc forms part of a cytoplasmic mega-complex, and binds 
to p53 in the cytoplasm, preventing its transport into the nucleus (Nikolaev et aL, 
2003). Interestingly, Parc is expressed at particularly high levels in 
neuroblastomas. Taken together, these data provide support for the involvement 
o f cytoplasmic sequestration o f p53 in tumourigenesis.
The intracellular localisation of p53 is also regulated by PML. PML is a tumour 
suppressor famous for its ability to promote the fomiation o f nuclear structures or 
foci referred to as nuclear bodies (NBs). PML co-recruits p53 and the
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transcriptional regulators p300/CBP to the NBs where p53 is acetylated by the 
HAT activity o f p300/CBP. This correlates with increased p53 activity (Wei et 
a l,  2003).
Resulation o f  p53 transcrivtion activation functions
Another level o f p53 regulation relates to the modulation o f its transcriptional 
activation function. p53’s old fiiend Mdm2 masks its trans activation domain 
through direct interaction and reduces its ability to activate transcription (Chen et 
a l,  1993; OXmQY et aL, 1993).
A number o f post-translational modifications have been implicated in the 
regulation o f p53’s transactivation functions. First, phosphorylation at the N- 
terminus which is associated with increased stability also enhances p5 3-dependent 
transcriptional activation. Moreover, phosphorylation at the C-terminus stimulates 
the activity o f the protein. For example, phosphorylation o f serine 392, and 
serine 315 by casein kinase II and cyclin dependent kinases, respectively, 
upregulates the transcriptional activity o f p53, potentially through stimulation of 
DNA binding (Blaydes et aL, 2001; Hupp et aL, 1992). Moreover, 
phosphorylation can confer promoter specificity to p53 transactivation as 
illustrated by phosphorylation at serine 46 which is required for the induction of 
A IP l expression (Oda et aL, 2000).
N-terminal phosphorylation o f p53 has been suggested to facilitate its acétylation 
by p/CAF and to increase its interaction with p300 (Sakaguchi et aL, 1998, 
Dumaz and Meek, 1999). As p53 acétylation is induced by DNA damage, and
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inhibited by Mdm2 (Ito et aL, 2001), it is not uni'easonable to postulate an 
important role for this modification in p53 activity. However, although there is 
some evidence for the ability o f acétylation to increase the transcriptional activity 
o f p53, its significance and mechanisms o f action remain unclear and 
controversial (Prives and Manley, 2001).
Finally, SUMO modification o f p53 at lysine 386 has also been reported to 
positively regulate p53 transactivation. However, this modification does not 
seem to be absolutely necessary for p53 activity and only affects a small 
proportion o f cellular p53 (Rodriguez et aL, 1999).
1-1.5 Feedback loops in the regulation of p53
An emerging theme in p53 research is the involvement o f feedback loops in the 
regulation o f p53 activity. p53-inducible genes appear to cluster into different 
categories according to the function o f the proteins they encode. A particular 
class o f these genes seems to be involved in the regulation o f p53, the most 
famous example being the mdm2 gene. The negative feedback loop formed 
between Mdm2 and p53 is responsible for maintaining low levels o f p53 under 
normal conditions, and is regulated by several cellular mechanisms that allow the 
release o f p53 and its activation in response to stress (Alcaron-Vargas and Ronai, 
2002).
Moreover, p53 also induces the expression o f proteins that regulate Mdm2 
function. Examples include cyclin G (Okamoto and Beach, 1994), which recruits 
the serine/thi'eonine phosphatase PP2A to Mdm2, resulting in its
33
déphosphorylation, and increasing its ability to promote p53 degradation 
(Okamoto et al., 2002). Conversely, the tumour suppressor PTEN inhibits 
PIK3/Akt signalling, thus blocking the ability o f AKT to promote nuclear entry of
M d m 2 l This restores the trans activation function o f p53 and allows its
V..
accumulation (Mayo et aL, 2002).
In addition to regulation o f Mdm2, p53 can induce, or repress mechanisms 
involved in its own regulation. 14-3-3 sigma, whose expression is induced in 
response to y irradiation in a p53 dependent mamier (Hermeking et aL, 1997), can 
bind the C-terminus o f p53 and increase its sequence specific DNA binding 
activity (W atennan et aL, 1998). Conversely, a negative feedback loop has been 
suggested between p53 and Clikl and Chlc2, two kinases implicated in the 
phosphorylation and stabilisation o f p53 in response to DNA damage. p53 
expression has been suggested to downregulate the mRNA levels o f both Chkl 
and Chk2 (Gottifindi et aL, 2001; Tominaga et aL, 1999).
Furthermore, a negative feedback loop has been proposed between p53 and ARE, 
the alternative product encoded by the mammalian CDKN2A locus. Whereas 
ARE promotes p53 stabilisation by interfering with the Mdm2-mediated 
degradation o f p53, p53 has been shown to negatively affect ARE expression and 
an inverse correlation has been demonstrated between ARE expression and p53 
status in tumour cells (Pomerantz et aL, 1998; Stott et aL, 1998).
34
The advantage conferred by feedback loops is that they allow tight and 
appropriate regulation of p53 under noimal conditions. Whereas positive feedback 
loops can contribute to the amplification of the response, negative feedback loops 
ensure that the p53 response is only induced when necessary, i.e. in the presence 
o f stress.
1-1.6 Conclusions
The p53 tumour suppressor plays a critical role in the prevention o f 
tumourigenesis by restraining the proliferation o f cells with potentially oncogenic 
lesions. This function o f p53 relates to its ability to respond to diverse stress 
signals and to translate these into appropriate cellular responses.
The importance o f  p53 function is reflected in the complexity o f  mechanisms 
regulating its function. The oncoprotein Mdm2 plays a central part in p53 
regulation and the relationship between the two proteins is far from being a simple 
linear mechanism as it is modulated by diverse signalling pathways which act 
through multiple protein-protein interactions and post-translational 
modifications.
Due to its inactivation in a large subset o f tumours, p53 is a very attractive target 
for the development o f cancer therapies. Consequently, a fuller understanding o f 
p53 function, and the mechanisms controlling its activity would provide 
invaluable tools for the treatment o f cancer.
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l . L  T h e  d53 re sp o n se
p53 mediates the cellular response to various stress signals. These 
signals commonly result in post-translational modification o f the 
protein and cause its stabilisation.
p53 activation generally inhibits cell growth, either by cell cycle 
arrest or apoptosis. The choice o f response is influenced by 
cofactor molecules such as JMY and ASPP.
Other outcomes o f p53 activation have been reported, including 
DNA repair, senescence and regulation o f angiogenesis. The level 
o f the p53 response is regulated by stress signals as well as 
autoregulatory loops involving p53 and products o f its target 
genes.
The diagram was adapted from Lu and Vousden, 2000.
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1-2. Mdm2. master regulator of p53:
Tumour development occui'S as a result o f multiple events that cause the 
deregulation o f cellular pathways governing normal cell proliferation, as well as 
pathways that repair and prevent the propagation o f potentially harmful lesions. 
Inappropriate expression o f oncogenes is one such event and can occur via many 
mechanisms, including mutation, translocation and gene amplification.
One of the cytogenetic manifestations o f gene amplification is in the form of 
paired, acentric cliromatin bodies referred to double minutes (DMs). These 
regions often contain amplified genes involved in the control o f cell proliferation 
and tumourigenesis (Cahilly-Snyder et al, 1987).
A search for genes located in double minutes in the spontaneously transfonned 
3T3 DM mouse cell line led to the identification o f the mdm2 gene (murine 
double minute), which was amplified in these cells (Cahilly-Snyder et aL, 1987). 
The oncogenic abilities o f mdm2 were demonstrated by its contribution to cell 
immortalisation and transfoiination in several independent studies. For example, 
overexpression o f the mdm2 gene in rodent cells led to their transfoimation 
(Fakliarzadeh et aL, 1991). Also, whilst overexpression o f mdm2 alone was 
sufficient to immortalise primary fibroblasts, co-expression o f activated ras led to 
a transformed phenotype (Finlay, 1993).
The early nineties were an exciting time in the Mdm2 field. The human gene was 
mapped to chromosome 12ql3-14 and was shown to be amplified in sarcomas
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(Oliner et al., 1992). More crucially, Mdm2 was shown to interact with the 
tumour suppressor p53 and to inlribit its transcriptional activation and growth 
inhibitory functions (Mommand et al., 1992; Finlay,1993; Barak et al., 1993; 
Oliner et aL, 1993). The ability o f Mdm2 to regulate p53 activity provided an 
explanation for its oncogenic properties and it was not long before Mdm2 became 
the focus o f intensive research which highlighted its key role in p53 regulation.
1-2.1 Mdm2 gene structure and protein domains 
Mdm2 sene structure and protein domains
The mdm2 gene has two different promoters PI and P2, which lead to transcripts 
initiating at different AUG codons. The upstream promoter PI is constitutively 
active and allows low levels o f mdm2 expression. P2 is downstream fiom p53 
binding sites located in the first intron o f the gene, and is induced by p53. 
(Freedman et aL, 1999). The ability o f p53 to induce mdm2 transcription is the 
basis o f the autoregulatory feedback loop which is crucial for regulation o f p53 
activity.
The regulation o f mdm2 gene expression is rather complex and multiple mRNA 
splice forms are expressed to give rise to different Mdm2 proteins (Momand and 
Zambetti, 1997). For example, in the 3T3 DM cell line, fiom which mdm2 was 
originally identified, five Mdm2 polypeptides have been identified with sizes 
ranging from 57 to 90 kilodaltons (kDa) (Olson et aL, 1993) Nevertheless, the 
distinctive functions o f the multiple forms o f Mdm2 remain elusive.
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M dm2 vrotein domains
The largest Mdm2 protein consists o f 489 amino acids in the mouse and 491 
amino acids in humans and contains several evolutionarily conserved domains 
(figure 1.2).
The first conserved domain resides in the amino-temiinus (residues 19-102), 
which is necessary for p53 binding, and sufficient to inhibit its transcriptional 
activation and gi*owth arrest functions (Chen et aL, 1993, W u et aL, 1996).
Mdm2 also contains a domain rich in acidic residues located between amino acids 
221-472, which allows its interaction with the ribosomal protein L5 (Maréchal et 
aL, 1994), as well as with the ART tumour suppressor protein (Pomerantz et aL,
1998). This region is also important in the regulation o f p53 stability. Deletion 
mutants in this region promote p53 stabilisation in a dominant negative fashion, 
indicating the importance o f this region in the degradation function o f Mdm2 
(Argenitni et aL, 2001).
Additional structural features o f Mdm2 include a zinc finger m otif between 
residues 305-322, and a ring finger domain at amino acids 438-478 (Lozano and 
Montes Oca Luna, 1998). Ring finger motifs are protein-protein interaction 
motifs with an ability to interact with DNA and RNA in some cases. The Mdm2 
ring finger has been shown to bind specific RNA sequences or stmctures in vitro 
(Elenbaas et aL, 1996). Importantly, the ring finger domain o f Mdm2 possesses 
E3 ubiquitin ligase activity (Fang et aL, 2000). E3 ligases catalyse the final step 
o f ubiquitination, which involves the transfer o f an activated ubiquitin molecule
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onto their substrate. This function o f Mdm2 is crucial for the regulation of p53 
and Mdm2 stability (Fang et aL, 2000).
Other key features o f Mdin2 include sequences involved in its sub-cellular 
localisation. The conserved basic nuclear localisation signal (NLS) is in close 
proximity to a nuclear export signal (NES) and these sequences allow the 
shuttling o f Mdm2 between the nucleus and the cytoplasm (Roth et aL, 1998). 
Moreover, a nucleolar localisation signal (NoLS) has been identified in the C~ 
terminus o f Mdm2, which is not functional in the absence o f stress. However, this 
signal cooperates with the NoLS o f  the tiunour suppressor p i 4"^^  ^ to allow the 
relocalisation of both proteins to the nucleolus (Lolirum et aL, 2000).
1-2.2 Mdm2 negatively regulates p53 function
The most important laiown function of Mdm2 is the negative regulation o f p53. 
Mdm2 binds to p53 and inliibits its activity at multiple levels; namely, 
transcriptional activation, stability and sub-cellular localisation.
Inhibition o f  p53~dependent sene expression
Mdm2 inhibits p53-dependent transcription by directly interacting with, and 
masking its trans activation domain (Mommand et aL, 1992; Oliner et aL, 1993). 
This region o f p53 is required for its interaction with components o f the 
transcriptional machineiy, including the TATA-binding protein (TBP), and 
transcription associated factors such as TAFn32 and TAFu 70 (Thut et aL, 1995; 
Lu and Levine, 1995). The partial overlap o f interaction sites o f Mdm2 and
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components o f the transcriptional machinery on the transcriptional activation 
domain o f p53 provides a biochemical mechanism for Mdm2-mediated inliibition 
of p5 3-dependent transcription.
In addition to interacting with components of the transcriptional machinery, p53^s 
transactivation function depends on the presence o f the transcriptional 
CO activators p300/CBP (Avantaggiati et aL, 1997; Lill et aL, 1997, Thomas and 
White, 1998). p300/CBP interact with p53, promoting its acétylation, which 
potentially enhances its function as a transcription factor (Prives and Manley, 
2001). Overexpression o f Mdm2 has been shown to reduce p53 acétylation by 
p300/CBP, a function that requires binding to both p53 and p300/CBP (Inoue et 
aL, 2001).
Interestingly, Mdm2 also interacts with p300/CBP, and has been proposed to 
inliibit the association o f the p53 N-terminus and p300/CBP, thereby down- 
regulating p53 transactivation (Wadgaonlcar and Collins, 1999).
Finally, fusion o f Mdm2 to a heterologous DNA-binding domain revealed its 
ability to repress p53-dependent and -independent transcription in an in vitro 
transcription system. This suggested an additional mechanism o f inhibiting p53 
transactivation, involving intrinsic repressor activities o f Mdm2 (Thut et aL, 
1997).
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Resulation o f  v53 stability
One o f the ways in which Mdni2 regulates p53 function is by targeting it for 
degradation by the 26S proteasome pathway (Haupt et aL 1997; Kubutat et al., 
1997). Mdm2 acts as a ubiquitin ligase (E3) for p53 and this function depends on 
the ring finger (Fang et aL, 2000), as well as the central acidic domain o f Mdm2 
(Meulmeester et aL, 2003, Kawai et aL, 2003).
Another requirement for Mdni2-dependent p53 degradation is the p300 
coactivator. It has been demonstrated that most o f the endogenous Mdm2 is in 
complex with p300 (Grossman et al., 1998), and that this interaction is essential 
for p53 degradation. Overexpression o f a C/H l polypeptide, comprising the p53 
and Mdm2 binding regions on p300 acts in a dominant negative manner to 
increase p53 stability, whereas Mdm2 mutants that are defective in p300 binding 
are compromised in their ability to promote p53 degradation but not its 
ubiquitination (Zhu et al., 2001).
Resulation o f  the subcellular localisation o f  v53
Mdm2-directed ubiquitination o f p53 has been implicated in p53 export. This is 
supported by studies in which mutation o f the ring finger domain abrogates the 
ability o f Mdm2 to stimulate p53 export (Boyd et aL, 2000; Geyer et al., 2000). 
Moreover, Mdm2 is also unable to promote p53 export at the restrictive 
temperature in a cell line containing a temperature-sensitive mutation in the E l 
ubiquitin charging enzyme. Re-introduction o f wild type E l enzyme restores
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Mdm2-driven p53 export, highlighting the importance o f Mdm2-mediated 
ubiquitination for p53 export (Boyd et aL, 2000).
Finally, the acidic region o f Mdm2 has also been implicated in its ability to 
ubiquitinate p53 and this was correlated with nuclear export (Kawai et aL, 2003). 
These obseiwations support a model in which ubiquitination o f p53 by Mdm2 
activates its nuclear export signal (possibly by unmasking), thus allowing its 
transport into the cytoplasm.
1-2.3 Regulation of the p53-Mdm2 feedback loop
The functional interaction o f Mdm2 and p53 forms a negative feedback loop 
wherein p53 upregulates Mdm2 and Mdm2 downi'egulates p53. This loop serves 
to keep p53 function under tight control, and its physiological relevance was 
demonstrated by the early embryonic death o f mdm2 null mice. This phenotype is 
completely rescued by deletion o f the p53  gene, indicating that embryonic 
lethality is the result o f excessive, uncontrolled p53 activity, and pointing to 
Mdm2 as a principal regulator o f p53 (Jones et aL, 1995).
However, for p53 to respond to stress signals, the feedback loop has to be 
interrupted. This is thought to result form the many cellular signals that feed into 
the p53-Mdm2 circuit, and involves post-translational modification o f p53 and 
Mdm2, regulation o f Mdm2 levels, as well as the action o f  a number o f 
cooperating proteins (fîgurel.3).
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Post-translational modification o f  p53
The major phosphorylation events thought to impinge on the p53-Mdni2 inteiplay 
involve phosphorylation sites in the N-terminus o f p53, within and near the Mdm2 
binding site. DNA damage-induced phosphorylation o f different sites in p53 is 
well documented and has been proposed to abrogate its interaction with Mdm2, 
thus relieving inhibition by Mdm2 (Alarcon-Vargas and Ronai, 2002).
Nevertheless, mutation o f all the phosphorylation sites on p53 to non- 
phosphorylatable residues yields a protein that is comparable to wild type p53 in 
teiins o f Mdni2 binding, sensitivity to Mdni2-mediated degradation, and 
stabilisation by DNA damage (Ashcroft et aL, 1999, Blattner et aL, 1999). On the 
other hand, mutation o f serines 15 and 37 to aspartic acid, which mimics the 
phosphorylated state resulted in slight resistance to Mdni2-dependent degradation. 
These observations suggest that phosphorylation can contribute to p53 
stabilisation without being absolutely essential (Ashcroft et a l , 1999).
Post-translational modification and down-resulation ofM dni2
The dissociation o f p53 phosphorylation from its stabilisation by DNA damage 
raised the possibility that DNA damage results in the modification o f other 
molecules involved in p53 regulation. Being a major regulator o f p53, Mdm2 was 
an attractive candidate and has been shown to be a phosphorylation target for a 
number o f kinases (Hay and Meek, 2000).
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Mdm2 phosphorylaytion on serine 395 by the ATM kinase has been reported to 
occur prior to p53 accumulation in response to ionising radiation (IR) (Khosravi et 
a l,  1999, Maya et al., 2001). An Mdm2 mutation that mimics phosphorylation at 
this site does not affect the binding o f Mdm2 to p53 but compromises its ability to 
destabilise p53 and promote its nuclear export (Maya et a l, 2001).
Similarly, c-Abl mediated phosphorylation o f Mdm2 on tyrosine 394 was 
suggested to reduce M dm2’s ability to promote p53 degradation, as well as its 
ability to inhibit p53 transcription and apoptosis (Goldberg et al., 2002). As both 
ATM and c-Abl have been implicated in p53 stabilisation in response to DNA 
damage, it is conceivable that regulation o f both components o f the p53-Mdm2 
feedback loop by the same kinase ensures a well-coordinated p53 response (Maya 
et al., 2001; Goldberg et a l ,  2002).
Mdm2 phosphorylation is not exclusively associated with down-regulation o f its 
effect on p53. Phosphorylation o f at least two residues, serines 166 and 186 is 
mediated by the Alct serine jllireonine kinase in response to mitogenic signals 
(Mayo and Domier, 2001; Zhou et a l ,  2001; Ashcroft et al., 2002). This allows 
nuclear entry o f Mdm2 and enhances its ability to interact with p300 (Mayo and 
Domier, 2001; Zhou et al., 2001). Consequently, M dm2’s ability to inhibit p53 is 
enhanced, an effect reversed by blockade o f the FI3/Akt signalling pathway 
(Mayo and Domier, 2001).
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Regulation o f Mdm2 levels has also been linked to p53 stabilisation in response to 
certain DNA damaging agents. Alkylating agents and UV radiation have been 
reported to reduce the levels o f Mdm2 mRNA and protein, and to decrease p53 
ubiquitination, providing an additional mechanism o f p53 activation (Inoue et a l,  
2001).
Résiliation o f  the o53-Mdm2 loop by interacting uroteins 
AR E
The ART tumour suppressor contributes to the stabilisation o f p53 in response to 
oncogene activation. The ART protein binds directly to Mdm2 and inliibits 
Mdm2-dependent p53 ubiquitination (Pomerantz et a l ,  1998; Honda and Yasuda,
1999). Furtheimore, at least when expressed at high levels, ARF can sequester 
Mdm2 in the nucleolus, thus physically preventing its interaction with p53 (Weber 
et aL, 1999).
Rb
Mutations or inactivation o f both p53 and Rb are very commonly found in 
tumours. p53 is involved in the regulation of Rb phosphorylation through 
activating the expression o f the cyclin kinase inhibitor p21. Moreover, Rb can 
affect p53 levels and function through its interaction with Mdm2. The binding o f 
Rb to Mdm2 prevents its ability to promote p53 degradation, and inlribits its anti- 
ap opto tic functions (Hsieh et aL, 1999).
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H IF - la
H IF -la  is the regulated component o f the hypoxia responsive HIF transcription 
factor, and has been implicated in the stabilisation o f p53 in response to hypoxia. 
This is thought to involve the interaction o f H IF -la  and Mdm2, which prevents 
Mdm2-mediated ubiquitination, degradation and nuclear export o f p53. 
Furthermore, co-expression o f H IF -la  in a reporter assay abrogated the ability of 
Mdm2 to repress transcription in a transient transfection assay. These data 
provide a potential mecharrism for the regulation of the p53-Mdm2 loop under 
conditions o f hypoxia (Chen et a l ,  2003).
TSG lO l
TSGlOl is a ubiquitin conjugase (E2)-like protein whose levels were found to 
decrease in the presence o f high levels o f Mdm2. Conversely, TSGlOl can 
prevent Mdm2 degradation by the proteasome, and thus may form a negative 
feedback loop with Mdni2. This regulatory circuit might impinge on the p53- 
Mdm2 loop since the lethal phenotype o f tsglOl'^' mice is partially rescued by the 
concomitant deletion o f p53  (Li et a l ,  2001, Ruland et a l,  2001).
1-2.4 p53-independent functions ofMdm2
Overexpression o f Mdrn2 contributes to human tumour formation, and this is 
largely attributed to its ability to inliibit p53 function. However, as the list o f 
Mdm2-interacting proteins is becoming progressively longer (figure 1.2), several 
lines o f evidence point to additional p53-independent functions o f Mdm2, which 
could potentially contribute to tumour fomiation.
First, if  the oncogenic potential o f Mdm2 ^ e re  restricted to the down-regulation 
o f p53, inappropriate expression o f Mdm2 in tumours carrying p53 mutations 
would be a redundant event. However, mdm2 gene amplifications and p53  
mutations have been reported to occur in a rare subset o f tumours. These tumours 
are more aggressive than tumours carrying one o f the two alterations (Cordon- 
Carlo et a l ,  1994). Moreover, splice variants o f Mdm2 lacking the p53-binding 
domain have been found in certain hmnan tumours, and these appear to retain 
their transforming abilities (Sigalas et aL, 1996).
Another line o f evidence comes from transgenic mice with targeted 
overexpression of Mdm2 in the mammary epithelium (Lundgren et aL, 1997). 
High levels o f Mdm2 resulted in hyperplasia o f the ducts o f breast tissue, as well 
as lack o f temiinal differentiation and polyploidy. This phenotype was 
maintained despite crossing into a p53  null background, but was not obseiwed in 
p53  null mice that do not overexpress Mdm2. These observations suggest that the 
tumourigenic activities o f Mdm2 in this situation do not involve p53 inhibition 
(Lundgren fl/., 1997).
Several characteristics o f Mdm2 could contribute to its p53-independent 
oncogenic potential. As discussed below, Mdm2 forms an interacting partner for 
a number o f proteins involved in the control o f cellular proliferation and/ or 
differentiation (figure 1.2. A). Some o f these interactions are sunmiarised below.
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In addition to stmctural similarities, the p53 homologue p73 shares some 
functional properties with p53, namely induction o f cell cycle arrest and 
apoptosis. Mdm2 interacts with p73 and inhibits its transactivation and apoptotic 
function without promoting its degradation, or nuclear export. Moreover, Mdm2 
dismpts the interaction of p73 and p300 by competing with p73 for binding to the 
N-terminus o f p300 (Zeng et al., 1999). It can also promote the redistribution o f 
p73 to nuclear aggregates, indicating divergent regulatory mechanisms for p53 
and its homologue (Gu et aL, 2001).
E2F-1
An exciting candidate for regulation by Mdm2 is E2F-1. Mdm2 interacts with the 
E2F1/DP-1 heterodimer and increases E2F-1-mediated transactivation in an 
overexpression assay (Martin et aL, 1995). Moreover, Mdm2 cooperates with 
E2F-1/DP-1 to stimulate DNA synthesis but also promotes the degradation o f the 
heterodimer. This has been proposed to reduce the abundance o f the heterodimer 
to levels appropriate for the G l-S  transition but that are insufficient for the 
induction o f apoptosis (Loughran and LaThangue, 2000).
FML
The tumour suppressor PME is a nuclear phosphoprotein that characteristically 
localises to distinct nuclear foci referred to as PME nuclear bodies (NBs).
PML'^' mice have an increased susceptibility to carcinomas following treatment 
with tumour promoting agents, and the cells derived from these mice display
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resistance to apoptosis (Wei et aL, 2003, and references therein). The 
mechanisms o f tumour suppression by PML remain unclear but apparently depend 
on its crucial role in the formation o f NBs. Furthermore, PML can stimulate p53 
activity by recruiting it, together with the transcriptional co activators CBP/p300 to 
the PML NBs, where p53 acétylation by its coactivators is believed to enhance its 
function as a transcription factor (Pearson et aL, 2000).
Mdm2 interacts with PML and promotes its relocalisation to the cytoplasm, and 
reduces its ability to stimulate the transcriptional activity o f a Gal4-CBP fusion 
protein (Wu et aL, 2003). As the proper localisation of PML is important in its 
function, it has been proposed that Mdm2-mediated export could contribute to the 
inhibition o f PML function (Wei et aL, 2003).
Furthermore, M dm2’s contribution to tumourigenesis could also involve the 
inhibition o f tissue/cell type transcription factors:
] \ iv o D
Amplification o f the mdm2 gene has been described in certain rhabdomyosarcoma 
cell lines displaying a non-differentiating phenotype (Fiddler et aL, 1996). In 
such cells, transfection o f an anti-sense mdm2 induced muscle specific gene 
expression, suggesting that Mdm2 is responsible for the lack o f muscle specific 
gene expression and also for the lack o f differentiation o f  these cells. One 
possible explanation for this effect o f Mdm2 is its ability to block the
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transcriptional activity o f the muscle-specific transcription factor Myo D (Fiddler 
et aL, 1996).
Numb
Numb is involved in cellular signalling and is believed to act as a determinant o f 
neural cell differentiation and/or cell fate (Juven-Gershon et aL, 1998).
Mdm2 interacts with and promotes the ubiquitination and degradation o f the 
mammalian Numb protein. Moreover, elevated levels o f Mdm2 can also promote 
the nuclear export o f Numb (Juven-Gershon et aL, 1998; Yogosawa et aL, 2003 ). 
Thus, the ability o f Mdni2 to regulate Numb levels may indicate a role o f Mdm2 
in cell differentiation or cell fate.
1-2.5 Mdm2 as a target for cancer therapy
Mdm2 is an attractive target for cancer therapy because o f its pivotal role in p53 
regulation. Blocking the Mdm2-p53 interaction would relieve Mdm2-imposed 
inliibition and allow the accumulation and activation o f p53. This has been 
shown by the use o f a synthetic protein which blocks p53 binding (Bottger et aL, 
1997). This protein greatly elevates the levels o f p53, and induces its 
transactivation and cell cycle arrest functions in a comparable manner to DNA 
damage. Moreover, micro-injection of a monoclonal antibody against the p53 
binding domain o f Mdm2 blocks the association o f p53 and Mdm2 and allows the 
activation o f p53 reporter genes (Bottger et aL, 1997).
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Another mechanism o f relieving inliibition o f p53 by Mdm2 would be to reduce 
the levels o f Mdm2 in cell lines that overexpress it. The use o f anti-sense 
oligonucleotides for the mdm2 message induces p53-dependent gene transcription 
and apoptosis in cell lines overexpressing Mdm2 and caiTying wild type p53 
(Chen et aL, 1998).
Although these and other results are encouraging, and show the therapeutic 
potential o f targeting Mdm2 to interrupt the p53~Mdm2 regulatory circuit, the 
transition from experimental systems to in vivo dmg administration has proved 
difficult due to physio-chemical properties o f certain inliibitors, as well as the 
incredible diversity displayed by tumours (Chêne, 2002)
1-2.6 Conclusion
The Mdm2 oncoprotein is a fascinating molecule, not only because o f its ability to 
closely control p53 activity, but also because o f its potential partnership with 
other regulators o f cell gi'owth and differentiation.
The relationship between p53 and Mdm2 provides a well established example o f 
the relationship between a tumour suppressor and an oncoprotein. The ability of 
Mdm2 to regulate p53 is coordinated with cellular conditions, thus ensuring that 
p53 inactivation is restricted to normal conditions, and allowing p53 to break free 
in response to stress.
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An emerging pattern in the regulation o f the p53-Mdm2 circuit is the 
simultaneous regulation o f both partners by the same kinase. This adds precision 
to the coordinated regulation o f the two proteins.
hi addition to its critical role in p53 regulation, the p53-independent properties of 
Mdm2 are likely to contribute to its oncogenic potential. Therefore, elucidating 
the physiological significance o f these properties would further our understanding 
o f the role o f Mdm2 in cellular transfoimation.
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i.2. S tr u c tu r a l  fe a tu re s  o f  M d m 2
The functional domains o f Mdm2 are shown. NTS, nuclear 
localisation sequence; NES, nuclear export sequence; ZF, zinc 
finger domain; NoLS, nucleolar localisation signal. Some Mdm2 - 
interacting proteins and their sites o f interaction are shown ( Daujat 
et aL, 2001, Wei et aL, 2003).
® Phosphorylation events enhancing M dm2’s inhibition o f  p53
* Phosphorylation events inhibiting M dm2’s inhibition o f p53
Mdm2
P53 binding
Numb
NLS Acidic region ZF3 t
NES
p300 Rb
ARF
Ring finger
NoLS 
RNA binding
TBP
PML
PML
1.3 , R e s u la tio n  o f  th e  p 5 3 -M d m 2  fe e d b a c k  lo o p
The interplay between Mdm2 and p53 forms a negative feedback 
loop in which p53 upregulates Mdm2 expression (red arrow) 
whereas Mdm2 downregulates p53 (Blue arrows).
The loop is interrupted by stress signals, allowing the activation 
o f p53. DNA damage activates a number o f kinases with 
opposing effects on the activity and stability o f p53 and Mdm2. 
Other types o f stress may involve the activity o f p5 3-cooperating 
molecules such as ARF, HIF l a ,  and Rb.
Conversely, Akt-mediated phosphorylation o f Mdm2 enhances 
its ability to inhibit p53 function.
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1-3. Regulation of p53 by p300/CBP
Many protein-protein interactions have been implicated in the regulation o f p53 
activity. One o f the most important and most intensively studied o f these 
interactions is that with Mdm2 which was discussed in the previous section. 
Another major regulator o f p53 is the p300/CBP family o f proteins. These 
proteins act as co activators for p53. p300/CBP regulation o f p53 is more 
complex than simple stimulation o f transcriptional activity and involves 
cooperation with both positive and negative regulators o f p53.
1-3.1 P3Q0/CBP
The p300/CBP proteins are members o f a family o f proteins that, thi'ough 
contributing to various signal dependent-transcription events, participate in many 
physiological processes, including proliferation, differentiation and apoptosis 
(Shikama eï n/., 1997).
The cellular functions o f p300/CBP are compromised in a number o f diseases 
affecting the p300/cbp  genes. Haplo-insufficiency o f CBP causes Rubinstein- 
Taybi syndrome (RTS), a condition characterised by mental retardation, various 
physical abnomialities and increased predisposition to cancer (Petrij et al., 1995). 
Similar abnomialities are observed in mice heterozygous for a disruption in the 
cbp gene and these mice have an increased incidence o f leukaemias and certain 
types o f sarcomas (Tanaka et aL, 1997; Kung et aL, 1999). These data indicate 
that gene dosage o f CBP, and therefore, the level o f the protein, is important for
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its function and that despite sharing extensive homology, p300 caimot substitute 
for CBP function.
Mutation of the pSOO/cbp genes has been obseiwed in a number o f human 
tumours. Somatic mutations in the p300  gene have been observed in breast, 
gastric and colon cancer and are often associated with loss o f heterozygosity o f 
the second allele (Gayther et aL, 2000). Furtheraiore, chromosomal translocations 
involving the cbp and p300  genes are associated with certain fomis o f leukaemia, 
indicating a role in the proliferation and differentiation o f haematopoietic cells. 
Therefore, p300 and CBP display some classical features o f tumour suppressors 
(Gayther et aL, 2000),
p300/CBP function as coactivators in that they assist transcription by sequence- 
specific DNA binding transcription factors. A considerable number of 
transcription factors have been reported to interact with p300/CBP and to respond 
to its coactivating properties (figure 1.4)(reviewed in Shikama et aL, 1997). 
These include ligand-dependent nuclear receptors, transcription factors involved 
in myogenesis, and in mitogenic and semm-responsive signalling. Moreover, 
signal transduction by the JAK/STAT pathway in response to interferon 
stimulation utilises the coactivating properties o f p300/CBP (Shikama et aL, 
1997).
Competition among various transcription factors for limiting levels of p300/CBP 
has been proposed as a mechanism o f regulating transcription in response to
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different cellular signals. This is supported by studies demonstrating that the 
engagement o f p300/CBP in transcription by various hormone receptors inliibits 
AP-1-dependent transcription. Honnone signalling is often associated with 
differentiation and inhibition o f proliferation whilst AP-1 is involved in mitogenic 
signalling. Thus, it is possible that p300/CBP function is targeted to a specific 
subset o f transcription factors in response to various signal transduction pathways 
(Kamei et aL, 1996).
The ability o f p300/CBP to interact with a multitude o f transcription factors and 
with components o f the basal transcription machinery allows it to connect these 
molecules, allowing transcriptional activation (Shikama et aL, 1997).
Furthermore, the central domain o f p300/CBP contains a domain with histoire 
acetyltransferase activity (HAT), which allows the acétylation o f lysine residues 
in histoire tails, a process associated with transcriptional activity. The HAT 
activity o f p300/CBP also extends to the transcription factors themselves, 
enliancing their transcriptional activity (reviewed by Chan and LaThangue, 2001). 
In fact, many o f the tumour associated mutations o f the p300  gene result in loss of 
the acetyltransferase activity, indicating that the ability to acetylate one or more 
cellular proteins may be critical for the control of cell giowth (Gayther et aL, 
2000).
p300/CBP are also believed to mediate their function by acting as a platfoim for 
the assembly o f  multi-component coactivator complexes, which can also contain 
other HATS such as SRC-1 and P/CAF (Chan and La Thangue, 2001). The
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formation o f these multi-component complexes may seiwe to increase the relative 
concentration o f transcription regulatory proteins in the local transcription 
environment and facilitate protein-protein and protein-DNA interactions. Since 
many proteins interact with p300/CBP in response to various signals, the ability to 
nucleate the formation o f multi-protein complexes would also facilitate the 
integration of a variety o f cellular signals and would allow the coordination o f 
these signals with transcription. Finally, by forming different combinations o f 
these cofactors, the cell can generate a very large number o f regulatory complexes 
thi'ough combinatorial specificity and synergism (Chan and LaThangue, 2001).
1-3.2 p300/CBP and p53 regulation
The adenovirus E l A targets p300/CBP and can generally repress the aetivation o f 
promoters that utilise the coactivating properties o f p300/CBP, including p53- 
target promoters. The inability o f p300/CBP binding defective E l A mutants to 
repress p53-dependent transcription provided one o f the first clues to the role o f 
p300/CBP in p53 activity (Somasundaram and El-Deiry, 1997). Since then, 
numerous studies have proved the importance o f p300/CBP in the regulation of 
p53. The transfection o f E lA  was shown to inliibit p300/CBP and block p53- 
dependent transcriptional activation and apoptosis. Cotransfection o f full length 
p300 restores both functions o f p53 (Lill et aL, 1997). Moreover, p53-dependent 
apoptosis was abrogated by dominant-negative derivatives o f p300/CBP proteins. 
These, and many more studies have established p300 and CBP as critical 
regulators o f p53 function.
62
Acétylation o f  v53 by j)300/CBP
In addition to histones, the HAT activity o f p300/CBP targets p53 for acétylation 
at the C-teiininus (Gu and Boeder, 1997, Ito et aL, 2001). Acétylation o f p53 by 
p300/CBP, and also by P/CAF has been shown to be induced by a variety o f 
cellular stresses (Ito et aL, 2001), and to be stimulated by phosphorylation at the 
N-teiininus (Sakaguchi et a /.,1998). The initial studies suggested that acétylation 
entrances sequence specific DNA binding by p53 (Gu and Boeder, 1997; 
Sakaguchi et aL, 1998). However, this view has been challenged by many studies 
showing lack o f effect o f acétylation on DNA binding by p53. For example, 
comparison o f p53 acétylation mutants with the wild type protein in CHIP assays 
showed equal binding of both forms to the p21 promoter in U 20S  cells (Bariev et 
aL, 2001). The functional significance o f p53 acétylation is still ambiguous and 
the best current guess is that it might have a positive effect on transcriptional 
activity o f p53 without being absolutely and ubiquitously essential (Prives and 
Manley, 2001).
v53 stability and the Mdm2 connection
The multifunctional nature o f p300/CBP is highlighted by their dual role in the 
regulation o f p53. In contrast to their positive effect on p53-dependent 
transcription, p300/CBP are essential for the degradation o f p53 by its negative 
regulator Mdm2 (Grossman et aL, 1998). In fact, most o f the endogenous Mdm2 
is believed to be in complex with p300 and Mdm2 mutants that are defective in 
p300 binding lose their ability to promote p53 degradation (Grossman et aL, 
1998, Zhu et aL, 2001)
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p300/CBP contain three highly conserved cysteine and histidine-rich domains 
referred to as C /H l, C/H2 and C/H3. These domains are believed to be important 
in mediating protein-protein interactions and interact with a number of cellular 
and viral proteins. The most N -tenninal o f these, C /H l, has been shown to bind 
p53 as well as Mdm2. Overexpression o f this domain in osteosarcoma cells led to 
the stabilisation o f endogenous p53. This was dependent on C/H l binding to 
Mdm2 but not to p53 (Grossman et aL, 1998).
Further, p300 was shown to cooperate with Mdm2 in the polyubiquitination o f 
p53, thus acting as an E4 enzyme for p53 ubiquitination (Grossman et aL, 2003).
Recruitment o f  co factors
As discussed above, p300/CBP can act as a scaffold for the formation o f multi- 
component CO activator complexes which are appropriate for the particular 
transcription event. Because the molecular composition o f such complexes 
dictates their function, identification o f the individual components is crucial for a 
better understanding o f p300/CBP regulation and function. Co factors that interact 
with p300/CBP have been identified such as NAP and P/CAF (Shikama et aL, 
1997; Schütz and Nakatani, 2000),
Consistent with its role in p53 transactivation, p300 may also be involved in the 
recruitment o f cofators that enhance the p53 response. Two such cofactors, JMY 
and Strap, have been identified recently and have been shown to impact on p53 
function.
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1-3.3 JMY and Strap, novel cofactors for the p53 response 
JM Y and the v53 response
JMY (Junction mediating and reg u la to r protein) and p300 cooperate to augment 
the p53 response. This cooperation results from the ability o f the two proteins to 
interact directly with each other, and to be recruited to the p53 complex in 
response to DNA damage (Shikama et aL, 1999).
JMY is a 110 kDa protein with a number o f interesting features (figure 1.5). The 
N-terminal part o f the protein contains a cluster o f potential phosphorylation sites 
for S/T-P-directed kinases, including three consensus sites for cyclin-dependent 
kinases. A central region contains a domain with homology to the adenoviral 
CR2 conserved region. The C-temiinal half o f JMY contains a WH2 (lYiscott 
Aldrich Aomology) domain which in other proteins is associated with actin 
regulation, as well as a proline-rich domain (Shikama et aL, 1999, and 
unpublished observations).
Spliced variants o f JMY mRNA occur in certain types of cells. One o f these 
variants is translated into a protein isoform o f JMY, termed JMYAP, that neatly 
lacks the pro line rich region found in the C-terminus o f the wild type protein. The 
physiological significance o f this variant became clear when its effect on the p53 
response was compared to that o f the wild type protein.
Co-expression of JMY and p300 results in enhanced p53-dependent activation of 
the bax gene. However, the effect of JMY on other p53-responsive promoters, 
namely w afl/c ip l and indm2 is less pronounced. In contrast, JMYAP is less able 
to entrance transcription from the bax promoter. Given the role o f Bax in
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apoptosis, these data prompted the examination o f the role o f JMY and JMYAP 
in p 53-dependent apoptosis and growth arrest (Shikama et ah, 1999).
Wild type JMY efficiently enhances p53 dependent apoptosis whereas JMYAP 
has a negligible effect on apoptosis. hr corrtrast, JMYAP is more active at 
inducing cell cycle arrest relative to JMY (figure 1.6), These data suggest a 
potential role for the expression o f different JMY isofomrs in the modulation of 
the p53 response.
Strap: stress responsive activator o f  1)300
Strap, another component o f the p300 coactivator complex, was isolated as a 
JMY-interacting protein in a yeast two-hybrid screen. Strap is composed o f six 
tetratircopeptide repeat (TPR) motifs, which are geirerally involved in mediating 
protein-protein interactions (figure 1.5). This property o f Strap is reflected in its 
ability to interact with both JMY and p300 and to facilitate their interaction 
(Demonacos et ah, 2001).
As the name indicates. Strap is a stress responsive protein and is induced in 
response to a variety o f DNA-damaging stress signals, with a marked response to 
etoposide treatment. Stabilisation o f Strap further stimulates complex formation 
between JMY and p300, and also increases the association o f Strap with the p53 
complex.
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Consistent with its ability to interact with two p53 co factors, JMY and p300. Strap 
also increases p53 activity on p53-responsive promoters, and augments p53- 
dependent apoptosis. These functions o f strap correlate with its ability to override 
the inhibitory effect o f Mdm2 on p53 levels and transcriptional activity. The 
effect o f Strap on p53 activity is less pronounced in the absence o f Mdm2, 
suggesting that modulation o f the activity o f Mdm2 contributes to this function.
Taken together, these data point to an important role for Strap in the p53 response, 
which may involve the formation o f multi-cofactor complexes as well as 
modulation o f Mdm2 activity and of p53-dependent transcription (Demonacos et 
aL, 2001).
1-3.4 Conclusions
The p300/CBP coactivators occupy a central position in the complex cellular 
network controlling cell growth and differentiation. The formation o f p300/CBP- 
containing multi-protein complexes contributes to the cross-talk between diverse 
cellular signals and to the translation o f these signals into patterns o f gene 
expression.
p300/CBP are important regulators o f p53 activity and have opposing effects on 
the tumour suppressor. The dual function displayed by p300/CBP in p53 
regulation reflects their pleiotropic nature.
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p53 regulation involves multiple layers o f control which regulate every aspect o f 
its function. The identification o f p53 cofactors that can affect the outcome o f the 
response (as shown for JMY isoforms), or that can modulate p53 activity tlnough 
modulating its regulators (illustrated by the relationship between Strap and 
Mdm2) adds another level o f complexity to p53 regulation, hi order to ensure a 
coordinated response, such co factors would be expected to be under regulation. 
Understanding o f the regulatory mechanisms that impact on co activator function 
is, therefore, crucial for better understanding o f the p53 response, and can 
potentially provide novel targets for cancer therapy.
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1 ,4 , T h e  fu n c tio n a l d o m a in s  o f  v 3 00,
The cysteine/histidine-rich domains CH I, CH2 and CH3; the 
KIX domain and the bromodomain, Br, o f p300 are shown. CBP 
shows high sequence homology to p300. The N- and C-terminal 
domains o f p300/CBP can function as transactivation domains, 
and the central region accommodates the acetyl-transferase 
domain.
The pleiotropic nature o f p300/CBP is reflected in their ability to 
interact with proteins involved in various cellular processes. The 
regions involved in protein-protein interactions and some o f the 
interacting proteins are shown (Chan and LaThangue, 2001). 
The binding domains in p300 for JMY and Strap were taken 
from Shikama et aL, 1999 and Demonacos et aL, 2001; 
respectively.
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7.5. S tr u c tu r a l  f e a tu re s  o f  J M Y  a n d  S tra p
JM Y  :S/T-P region with a cluster o f potential phosphorylation 
sites for S/T-P directed kinases; CR2 : region with sequence 
homology to the adenoviral CR2 region; WH2, W iscott-Aldrich 
syndrome homology domain 2; P-rich, proline rich domain; 
Strap: I-VI, tetratricopeptide(TPR) motifs in Strap. Interaction 
domains for Strap, JMY and p300 are shown (Demonacos et 
a/.,2001).
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L 6 . P ro te in  iso fo rm s  o f  J M Y  a lte r  th e  o u tc o m e  o f  th e  v 5 3  
re sp o n se
JMY cooperates with p300 to enhance the p53 response and 
augment p53-dependent apoptosis. In contrast, the isoform 
JMYAP has compromised apoptotic activity and possesses 
greater cell cycle arrest activity than JMY.
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1-4. Control of protein function by regulation of nuclear 
transport
The exchange o f molecules between the nucleus and the cytoplasm is tightly 
regulated by the nuclear envelope. This ensures that genetic infomiation is 
protected and transmitted correctly, and facilitates the coordination o f nuclear and 
cytoplasmic processes (Corbett and Silver,!997). Access across the nuclear 
envelope involves the nuclear pore complexes (NPCs) (Feldherr et aL, 1984), 
which are large protein structures composed o f approximately 100 different 
proteins referred to as nucleoporins. Metabolites, ions and molecules smaller than 
40kDa can diffuse passively tluough the NPC, while larger molecules tend to be 
actively transported (Doye and Hurt, 1997).
Nuclear import and export mechanisms exhibit considerable diversity, and are, in 
certain cases, regulated rather than constitutive. The ability to regulate the nuclear 
transport o f certain molecules allows the integration o f intracellular and 
extracellular input signals, and the tailoring o f the cellular response to particular 
signals.
1-4.1 Basic steps of nuclear transport
Nuclear transport reactions (import or export) involve the same basic steps:
First, the transport cargo is recognised by, and associates with its transport 
receptor. This involves recognition o f nuclear transport signals in the cargo 
molecule. The next step involves docking o f the receptor-cargo complex at the 
nuclear envelope tlu'ough interaction o f the transport receptor with nuclear pore
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proteins. This is followed by the translocation of the transport complex tlirough 
the nuclear pore complex (NPC), and, finally, transport is terminated by 
irreversible dissociation o f the cargo-receptor complex, and transport receptors are 
recycled for use in an another round o f transport (Corbett and Silver, 1997).
1-4.2 Nuclear transport signals
Identification o f cargos by the transport machinery involves inherent czis;-acting 
signals within the cargo molecule. These show a great level o f diversity and 
include:
Nuclear localisation sisnals (NLS)
The classical NLS was the first transport signal to be identified and comprises a 
short stretch o f positively charged residues, generally lysine or arginine residues 
(Corbett and Silver, 1997). The bi-partite NLS contains two basic clusters of 
positively charged residues separated by a spacer region (Corbett and Silver, 
1997). Other nuclear localisation signals include ankyrin repeats in the NFkB 
inhibitor, l^B a  (Sachdev et aL, 1998.; Lee and Haimink, 2002) and the trimethyl- 
guanosine cap used in snRNA transport (Huber et aL, 1998).
Nuclear export sisnals (NES)
Nuclear export signals were first identified by mutational analysis o f proteins that 
are rapidly translocated fi'oin the nucleus to the cytoplasm. The best understood 
nuclear export signal (NES) is the leucine-rich NES in proteins such as the HIV 
Rev protein (Fischer et aL, 1995), and the protein kinase A inhibitor (Wen et aL, 
1995). Similarly to NLS signals, nuclear export signals show great variability but
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are generally characterised by a cluster o f hydrophobic residues; generally 
leucines but isoleucine and valine residues are also present in certain NESs 
(Corbett and Silver,1997).
Niicleocytovlasmic shuttlins sisnals (NS)
Nucleocytoplasmic shuttling signals are bi-directional transport signals (Michael 
2000). All proteins currently known to have a nucleocytoplasmic sequence are 
niRNA-interacting proteins.
The M9 m otif is an example o f an NS signal. It is much larger than a classical 
NLS (38 amino acids) and does not contain clusters o f basic residues. M9 has 
been implicated in both the import and export o f the RNA binding protein ImRNP 
A l, and these two functions proved to be inseparable (Michael^2000). In other, | ) 
less extreme cases, nuclear import and export functions o f the NS overlap but are 
spacially separable, and can be independent o f transport receptor binding, 
involving direct interaction with the NPC (Michael, 2000).
1-4.3 Nuclear transport receptors
Nuclear localisation signals are recognised by members o f the nuclear import 
receptor family. These receptors are generally large acidic proteins with an N- 
terminal RanGTP binding domain and an N-temiinal cargo binding domain. 
Another important feature o f these receptors is their ability to interact with 
components o f  the nuclear pore complex (Adam, 1999).
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Different types o f NLS appear to associate with distinct receptors (Nadler et al.,
1997). The im portina/p complex imports “classical NLS’’-containing proteins. 
While both subunits o f the import receptor can interact with NLS sequences, the a  
subunit displays stronger binding and is believed to be responsible for interaction 
with the NLS-bearing substrate while importin P mediates binding to the nuclear 
pore complex (Gorlich et a l ,  1995).
Other importin a /p  -like proteins have also been identified. For example, import 
o f the M9-containing luiRNP A l protein is mediated by the import receptor 
transportin, a distant relative o f importin p (Pollard et al., 1996), and the adaptor 
protein snurportin-1 has been shown to interact with importin p and mediate 
snRNA import (Huber et a l,  1998).
Studies o f nuclear export receptors have been gieatly facilitated with the use o f 
the antibiotic Leptomycin B. Leptomycin B was found to inliibit the export o f the 
HIV Rev protein, and to inliibit Rev-mediated RNA export (Fornerod et al., 1997; 
W olff et al., 1997). The ability o f leptomcin B to block export o f other NES- 
containing proteins indicated that it was an inliibitor o f the nuclear export 
machinery and identification o f the cellular target o f leptomycin B revealed the 
function o f CRM l as a nuclear export receptor. CRM l shows sequence similarity 
with importinp suggesting that nuclear transport receptors form a family o f 
proteins (Fornerod et al.\991', W olff et al., 1997).
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1-4.4 Cargo-receptor interaction
The directionality o f nuclear transport depends on the distribution o f transport 
receptors and the regulated association o f these receptors and their cargos.
The small GTPase Ran plays a crucial role in the directionality o f transport as it 
regulates the assembly and disassembly o f nuclear transport complexes.
Ran exists in two nucleotide-bound states: Ran GTP and Ran GDP. The 
distribution o f proteins that control the GTP/GDP-bound states o f Ran creates a 
steep gi-adient across the nuclear envelope such that Ran GTP localises mainly to 
the nucleus whereas Ran GDP is cytoplasmic (IzauiTalde et al., 1997, Nachury 
and Weiss, 1999).
The association of export receptors with their cargo requires interaction with 
RanGTP in the nucleus (Izaurralde et a l, 1997) and their dissociation occurs in 
the cytoplasm where Ran GTP is rapidly hydrolysed into the GDP-bound form 
(figure 1.7).
On the other hand, Ran GDP fonns a stable association with cargo-import 
complexes in the cytoplasm (Hopper et al., 1990, Mahajan et al., 1997). The 
cargo is released in the nucleus upon binding o f Ran GTP to the nuclear import 
receptor (figure 1.7). The importance o f the Ran GTP/GDP gi*adient is 
highlighted by in vitro experiments showing that when the Ran GTP/GDP 
giadient is inverted across the nuclear membrane, the direction o f the traffic is 
reversed (Nachury and Weis, 1999). Furthermore, depletion o f Ran GTP levels
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by sodium azide has been reported to block nuclear transport (Schwoebel et al., 
2002).
1-4.5 Regulation of nuclear transport
The multi-step nature of nuclear transport mechanisms provides several potential 
points o f regulation. These include regulation o f components o f the transport 
machinery and regulation o f the association between the receptor and cargo 
molecules.
Regulation o f  the transport machinery
The physiological state o f the cell has been suggested to dictate the rate o f nuclear 
transport and the maximum aperture o f the nuclear pore complex (Feldherr et al.,
1998). For instance, the passage o f cells from a quiescent to a proliferating, to a 
transformed cell increases the rate o f nuclear transport as well as the aperture of 
the nuclear pore complex (FeldheiT et a l,  1998).
Moreover, modification o f the nuclear pore complex may contribute to the 
regulation o f nucleocytoplasmic traffic. Kehlenback et a l ,  have recently shown 
that phosphorylation of a component o f the nuclear pore complex inhibits 
importin p and transportin-dependent import, without affecting CRM l-dependent 
export (Kehlenback et a l ,  2000).
Another mechanism o f regulation involves preferential use o f  transport factors. 
Mammalian cells contain three families o f importin a  proteins. Although there 
may be considerable functional redundancy among these, some evidence suggests
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the existence o f non-overlapping functions and specificity as illustrated by the 
import o f the transcription factor STATl which specifically requires importin a5 
(Sekimoto a/., 1997).
Resulation o f  transport throush resulation o f  carso molecules
a)Post~translational modification
Post-translational modification o f nuclear transport signals can affect the 
accessibility o f these sequences to the transport machinery and alter the affinity o f 
the cargo for receptors. Examples that illustrate the regulation o f nuclear transport 
by post-translational modification are summarised below.
Phosphorylation
Phosphorylation of the yeast transcription factor Pho4 allows its interaction with 
the export factor Msn5 (Komeili et al., 1999). Phosphate starvation provides the 
stimulus that triggers dephosphorylation o f a serine residue in the NLS. This 
relieves inlribition and allows the association o f Pho4 with the import receptor 
Psel (Kaffinan et al., 1998).
In contrast, phosphorylation o f signal rtansducers and activators o f hanscription 
(STATs) activates their transactivation function. STATs are involved in the 
interferon-mediated cellular response to viral infection (O’shea et al,, 2002). 
hiterferon stimulation activates the JAK kinases which in turn, phosphorylate 
tyrosine residues o f STATs, allowing their dimérisation and subsequent nuclear 
transport and DNA binding (O ’shea et al., 2002). Dephosphorylation o f STATs
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and their dissociation from DNA is believed to unmask their NES signal, allowing 
CRM l “driven nuclear export (O ’shea et al., 2002).
Méthylation
Méthylation of arginines has been proposed to affect the export o f  some yeast 
hriRNPs (Shell et al., 1998).
Ubiauitination
The oncoprotein Mdm2 negatively regulates the p53 tumour suppressor at 
multiple levels, including subcellular localisation"". Early studies suggested the 
function o f Mdm2 as a shuttling protein that can transport p53 out o f the nucleus 
(Roth et al., 1998). However, more recent findings demonstrated that the 
ubiquitin ligase activity o f Mdm2 rather than its nucleocytoplasmic shuttling 
properties is critical in regulating the nuclear exclusion o f p53 (Boyd et al., 2000; 
Geyer et a l, 2000). Since Mdm2 promotes p53 ubiquitination at lysine residues 
near the C-terminal NES, it was speculated that ubiquitination may reveal the p53 
NES and allow its nuclear export. This is supported by the inability o f p53 
ubiquitination mutants to undergo Mdm2-directed export (Lohrum et al., 2001).
b] Protein-vrotein interaction
M askins
Masking involves the competitive binding o f an accessory protein to the 
NLS/NES signal, which masks the signal from the import/export machinery.
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A well characterised example o f transport regulation by domain masking is the 
interaction between NFkB and its negative regulators, the IkB proteins. 
Association o f NFk B with its inhibitor masks one or both NLSs o f the NFkB 
subunits, and prevents its nuclear import (Huxford et a l, 1998, Malek et a l,
2001). Disruption o f the NFkB/IkB complex allows the import and nuclear 
localisation o f NFkB (Beg et a l ,  1993).
Nuclear/cytoplasmic anchoring and sequestration
This involves the immobilisation o f a protein within a specific cellular 
compartment. The tumour suppressor APC associates with cytoskeletal 
microtubules which might be important for anchoring APC in the cytoplasm 
(Smith et al., 1994). Also, p53 contains a cytoplasmic sequestration domain 
(CSD) which inhibits the association o f importin a  with the main NLS signal in 
the C-tenninus o f p53 (Liang et al., 1999).
Pissr^ Back
In certain cases, nuclear transport o f a particular protein is mediated by binding to 
another protein which bears a nuclear transport signal. The cyclin component o f 
cdk2/cyclin E and cdc2/cyclin B acts as a nuclear targeting unit for its partner 
kinase. Cyclin E binds to the import adaptor importin a  while cyclin B1 can 
interact directly tluough its NLS with the import receptor importin p. In addition 
to the NLS cyclin B1 also provides an NFS for its associated kinase (Yang et 
n/.,1998).
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1-4.6 Nuclear transport and regulation of cell proliferation and oncogenesis
A considerable body o f evidence supports the importance o f  factors such as 
protein modification, protein stability and protein-protein interactions in the 
regulation of protein function. In particular, proteins that control cellular 
proliferation are tightly regulated at multiple levels to prevent abnormal cell 
gi'owth and propagation o f potentially deleterious mutations. Regulated nuclear 
transport is emerging as an important mechanism regulating the function o f a 
variety o f proteins and this property is highlighted by deregulation o f the cellular 
distribution o f certain proteins in some cancers.
Cell cycle resiilatory yroteins
The intracellular localisation o f cyclin B1 is regulated tluoughout the cell cycle. 
It is believed to shuttle between the nucleus and cytoplasm during interphase. 
However, phosphorylation o f several serine residues at the begimiing of mitosis 
blocks CRM l binding, allowing nuclear accumulation o f cyclin B1 (Yang et a l ,  
1998).
Signal transduction
Regulated translocation o f components of signal transduction cascades can be an 
efficient mechanism o f coordinating fast and adequate cellular responses to a 
variety o f stimuli. Signal-induced translocation o f signaling proteins to their site 
o f action not only regulates their access of the downstream components o f the 
cascade, but also allows the signal to be rapidly amplified.
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The extracellular signal- regulated kinases (ERKs) 1 and 2 are cytoplasmic in 
unstimulated cells. Stimulus-dependent phosphorylation is thought to trigger the 
dimérisation, and nuclear localisation o f these kinases. An NES-dependent export 
mechanism is presumed to relocate the unphosphorylated forms o f ERKs to the 
cytoplasm (ICliokhlatchev et al., 1998).
Tum our suppressors
The importance o f nuclear transport in regulating the function o f tumour 
suppressors is highlighted by the obsei*vation that it is deregulated in certain 
tumours.
For example, BRCAl was reported to mislocalise to the cytoplasm in breast 
cancer derived cell lines and in certain breast carcinomas (Taylor et al., 1998). 
Further, abnormal cytoplasmic localisation o f p53 has been reported in breast 
carcinoma (Moll et al., 1992), neuroblastomas (Moll et al., 1995), and in 
colorectal cancers (Bosari et al., 1995). As discussed earlier, several mechanisms 
appear to regulate the subcellular localisation o f p53, including phosphorylation, 
ubiquitination, domain masking (tetramerisation) and cytoplasmic sequestration. 
The existence o f such a variety o f regulatory mechanisms supports the 
importance o f localisation for p53 function.
1-4.7 Conclusions
Recent developments o f the nucleocytoplasmic transport field have highlighted 
the complexity o f mechanisms governing the movement o f molecules between the 
nuclear and cytoplasmic compartments. The regulation o f nuclear transport
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involves the regulation o f the multiple components involved and the specificity o f 
their action.
Subcellular distribution is increasingly recognised as an important aspect o f the 
function o f numerous cellular factors involved in cell proliferation and 
tumourigenesis. Therefore, better understanding o f the mechanisms regulating 
subcellular localisation would provide important clues to the function o f such 
proteins.
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1,7 . N u c le a r  tr a n s p o r t a n d  th e  R a n  c y c le
Model for import and export o f molecules through the nuclear 
pore complex.
Import complexes assemble in the cytoplasm in the presence o f 
Ran GDP, and are translocated Into the nucleus. In the nucleus, 
binding o f RanGTP to the import complex causes its dissociation 
and cargo release.
Nuclear export complexes assemble in the nucleus in the 
presence o f RanGTP. Following translocation into the 
cytoplasm, GTP hydrolysis results in the release o f the cargo.
O Leptomycin B site o f action
O Azide site o f action

1-5. Objectives
The ability o f p53 to induce apoptotic cell death in response to stress signals is 
crucial for its function as a tumour suppressor. This property o f p53, frequently 
compromised in tumours, depends primarily on its function as a transcription 
factor and on its ability to form complexes with other transcriptional regulators 
that modulate its transcriptional activity.
The p300- associated cofactor JMY selectively augments p53-mediated apoptosis, 
and thus forms part o f a growing family o f cofactors that are required for p53- 
dependent apoptosis. The involvement o f such co factors in the p53 pathway 
indicates the existence o f additional mechanisms regulating the apoptotic 
response, the understanding o f which would prove invaluable in the development 
o f new therapies that restore p53 mediated apoptosis.
The work presented here focuses on the control o f JMY function, and aims to 
describe the mechanisms that allow it to co-operate with p53 under the 
appropriate conditions.
Previous studies have demonstrated that JMY is recruited to p53 complexes in 
response to stress. Therefore, it was o f interest to determine if  the intracellular 
localisation o f JMY was affected by cellular stress, and to examine the effect o f 
different cellular conditions on the cell cycle function o f JMY.
The activity o f p53 is partly regulated by its sub-cellular localisation and involves 
the activity o f its main regulator, Mdm2. Mdm2 promotes the export o f p53 into
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the cytoplasm, thus inhibiting its ability to activate gene expression. Considering 
the involvement o f both Mdm2 and JMY in p53 regulation and the ability o f 
Mdm2 to act as a shuttle protein, another objective o f this research relates to the 
ability o f Mdm2 to affect the cellular localisation o f JMY. The requirement for 
the ubiquitin ligase domain o f Mdm2 for such function led to questions about its 
ability to regulate the cellular levels o f JMY.
JMYAP, a protein isofonn o f JMY that lacks a proline-rich domain in the C- 
terminal region o f the protein, is also capable o f enhancing the p53 response. 
However, this isoform o f JMY favours p53-dependent G1 arrest as opposed to 
apoptosis. Considering that JMYAP possesses functional properties that 
distinguish it from wild type JMY, it was o f interest to assess whether the 
differences between these two isoforms were reflected in the control o f their 
subcellular localisation.
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Chapter 2. Materials and Methods
2-1. Plasmids
The following plasmids have previously been described: pcDNA3 HAJMY 
(Shikama et a l ,  1999), pCHDMIA, pCHDMA58-89, pCHDM C464A, pCH DM l- 
440 {C hoR eta l, 1993; 1996).
pCHDM A58-89;C464A was generated by restriction digest o f pCHDMC464A 
and pCHDMA58-89 with Sail. The fragments containing the C464A and the 
A58-89 mutations were ligated to generate a plasmid with both mutations.
2-2. Antibodies 
Primary antibodies
HA Mouse monoclonal H A l 1 (Babco)
Rabbit polyclonal Y -11 (Santa Cruz)
JMY Rabbit polyclonal 1289 (generated in the laboratory)
Mdm2 Mouse monoclonal A b-1 (Oncogene)
Mouse monoclonal SMP-14 (Santa Cruz)
Rabbit polyclonal H-221 (Santa Cmz) 
p53 Mouse monoclonal D O -1 (Santa Cruz)
Sheep polyclonal anti-p53 (Scottish Antibody Production Unit) 
CD20 L27 (Becton Dickinson)
Secondary antibodies
Anti-Ig AP Alkaline phosphatase-conjugated (Promega)
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Anti Ig HRP Horseradishperoxidase-conjugated(Amersham Biosciences)
Immunofluorescence Anti-mouse Ig-Alexa Fluor®488 (green)(Molecular Probes) 
Anti-rabbit Ig-Alexa Fluor® 594 (red) (Molecular Probes)
2-3. Drugs and DNA damaging agents
Actinoniycin D (Sigma) 20nM final concentration, incubated for 16 hours
Etoposide (Sigma) lOpM final concentration, incubated for 7 hours
Ultraviolet 60J/m^, cells harvested 6 hours later
Leptomycin B (Novartis) 1 pM final concentration, incubated for 5 hours
2-4. Transfection
Unless stated otherwise, ^ I s  were maintained in Dulbecco's modified eagle 
medium (DMEM) (Gibco BRL) supplemented with 10% (v/v) foetal calf serum 
(FCS) and the antibiotics streptomycin (10 mg/ml) and penicillin (lOOU/ml) 
(Gibco BRL). Cell cultures were maintained in a water-saturated 5% C 02 
atmosphere at 37°C.
Cells were plated out 12-15 hours prior to transfection, at 1.5x 10^ for 
immunoprécipitation ,' western blotting and flow cytometry, or 1x10^ for 
immunostaining.
For transfections based on calcium phosphate DNA precipitation, the gi'owth 
media was replaced by fresh media 2 hours prior to transfection. The indicated 
amount o f plasmid DNA was mixed with a CacE solution to give a final salt 
concentration o f 200 mM. The solution was added drop-wise to an equal volume 
o f 2x HEPES Buffered Saline (50 mM HEPES pH 7.1, 280mM NaCl, 1.5 mM
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Na2HP0 4 ), followed by gentle mixing. The mixture was incubated for 20 minutes 
at room temperature before being added drop-wise to the cells.
The backbone vector pcDNAS was used to maintain a constant amount o f 
transfected DNA among samples, and pCMVpgal was included as an internal 
control for transfection efficiency.
12-18 hours post transcription, cells were washed 3 times with PBS to remove 
excess precipitate and fiesh media was added. Cells were harvested 24-72 hours 
post transfection.
2-5. Immunofluorescence
Cells seeded onto 35mm glass coverslips were washed tlrree times in cold PBS 
and fixed in a solution o f 4% paraformaldehyde at room temperature for 15 
minutes. Following three washes in PBS, peimeabilisation o f the cells was 
perfoimed at 4°C for 5 minutes with a PBS solution containing 0.5% Triton X- 
100. Fixed cells were then incubated in a blocking 10% FCS PBS solution for 10 
minutes at room temperature. Primary antibodies diluted in 1% FCS PBS were 
incubated with the cells for 30 minutes at room temperature. Cells were then 
extensively washed in a 1% FCS PBS solution, and the secondary antibody was 
added in a 10% FCS PBS solution for 30 minutes. Anti-mouse or anti-rabbit IgG 
conjugated to Alexa Fluor®488 (green), or Alex a Fluor® 594 (red) (Molecular 
Probes) was used for detection. Coverslips were washed extensively, with 
addition of DAPI (4,6-Diamino-2-phenylindole) to the final wash. Finally, cells 
were mounted on microscope slides using Citifluor
93
(Citifluor Ltd) and imimmofluorescence was viewed under a fluorescence 
microscope (Olympus).
Where cellular compartmentalisation was quantified, the percentage o f cells with 
each cellular localisation was defined relative to the population o f transfected 
cells.
2-6. Immuncj^cipitation
Cells were washed twice in PBS and incubated in trypsin for 2 minutes at 37°C. 
M edia supplemented with 10% FCS was then added and the cells collected and 
centrifuged at 1000 rpm for 5 minutes. The cell pellets were washed three times 
in cold PBS, re-suspended in TNN buffer (50 inM Tris-HCl pH7.5, 150mM 
NaCl,0,5% NP-40, 5mM EDTA, 0.1 mM DTT, 0.5pg/ml leupeptin, 0.5pg/ml 
apotinin, 40pg/ml bestatin), and after a 30 minute incubation on ice, they were 
centrifuged at 13000 ipm for 30 minutes at 4°C. The cell extract was pre-cleared 
by incubating with protein G agarose for 30 minutes and then harvested and 
rotated on a wheel at 4°C with 35pi protein A agarose and l-4p l primary 
antibody. The reaction was left for 6-16 hours. The agarose beads were 
subsequently washed three times in TNN reaction buffer. Bound proteins were 
released into 3x SDS loading buffer (375mM Tris-HCl pH6.8, 30% glycerol, 
6%SDS, 0.015% Bromophenol Blue). The sample was boiled for 3 minutes and 
separated by SDS-PAGE and the proteins o f interest were detected by western 
blot with the appropriate antibody.
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2-7. Western blot analysis
Protein expression was detected by immobilisation o f cell extract onto a 
nitrocellulose membrane (Inverclyde Biologicals), blocking in a 5% milk PBS 
solution and detection with specific antibodies. All antibodies were diluted in a 
5% milk PBS solution. Primary antibodies were used at a 1:500-1:2000 dilution 
and secondary antibodies were diluted 1:5000. Two detection systems were used 
to amplify the signal. Horseradish peroxidase-conjugated secondary antibodies 
(Amersham Biosciences UK Ltd) were used with the Super Signal ® West Pico 
solutions (Pierce); and substrate tablets (Sigma Fast™ 5-Bromo-4-chloro-3- 
indoyl phosphate/nitro blue tétrazolium) were used for detection o f calf alkaline 
phosphatase conjugated secondary antibodies (Promega).
2-8. Phosphatase treatment of cell extracts
Phosphatase treatment o f cellular extracts was perfoimed by addition o f Ip l 
lambda protein phosphatase (New England Biolabs). The extracts were incubated 
with the phosphatase (final concentration 2000 U/ml) at 30°C for 1 hour prior to 
SDS-PAGE and western blot analysis.
2-9. Flow cytometry
U 20S cells were transfected with 5pg pCMV-HAJMY or pcDNA3 empty vector, 
and 8pg o f CD20 expression vector. Cells were serum starved for 16 hours, 
exposed to ultraviolet light 6 hours before harvesting, or harvested without 
treatment. In all cases, cells were haiwested 48 hours post-transfection. For flow 
cytometry analysis the cells were captured by monitoring the expression o f the
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cell surface marker CD20. After transfection cells were harvested by treatment 
with cell dissociation solution (Sigma) for 30-45 minutes at 37°C. Cells were 
washed in PBS by centrifugation at 2000 rpm for 3 minutes, and resuspended in 
200pl o f PBS containing 20pl o f a mouse anti-CD20 antibody (Becton 
Dickinson) conjugated to fluorescein isothiocyanite (FITC). The cell suspension 
was incubated on ice for 30 minutes followed by washing in cold PBS. Cell 
pellets were subsequently fixed by the drop-wise addition o f 50% ethanol/PBS 
solution and left overnight at 4 °C.
Cells were then washed in PBS and re-suspended in 500pl o f PBS containing 
propidium iodide (20p,g/ml) and RNAse (125 U/ml). Flow cytometry was 
performed on a Becton Dickinson fluorescence activated cell sorter. All cell 
populations were analysed at a rate o f 100-200 cells/second to prevent mis-read. 
To determine the cell cycle profiles o f transfected cells the intensity o f propidium 
iodide staining was analysed in cells positive for FITC staining. Using Cell Quest 
Pro software, the cell cycle profile o f 10000 transfected cells was analysed.
96
Chapter 3. The subcellular localisation of JMY is 
regulated by cellular conditions
3-1. Introduction
Many cancer-related molecules are regulated at multiple levels to ensure tight 
control o f cellular proliferation. Defects in these regulatory mechanisms can 
affect the cell/s response to external insults and to internal aberrations, and 
eventually lead, or contribute to the development and progression o f cancer.
Recent developments in the field of nucleocytoplasmic transport have provided 
insight into the mechanisms governing the cellular distribution o f proteins, and 
highlighted the importance o f subcellular localisation in protein function (Hood 
and Silver, 2000). AbeiTant intracellular localisation o f cancer-related molecules 
has been reported in certain cancers. Examples include the mis-localisation o f 
BRCAl to the cytoplasm in breast cancer cells but not normal cells (Taylor et al, 
1998), and cytoplasmic sequestration o f p53 in neuroblastomas, breast and colon 
cancers (Moll et al, 1992; 1995; Bosari et al, 1995).
The potent apoptotic and growth inhibitory functions o f p53 are tightly controlled 
by diverse mechanisms. These not only regulate the stability o f the protein and 
its ability to act as a transcription factor, but also impact on its intracellular 
distribution (Vousden, 2002).
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In addition to direct regulation o f the p53 protein, a growing number o f cofactors 
have been reported to modulate the outcome o f p53 activation (Lu and Vousden
2002). Such CO factors could potentially provide additional regulation points for 
the p53 response, and include the p300 cofactor JMY. JMY cooperates with p300 
to enlrance p53-dependent transcription and apoptosis (Shikama et a l ,  1999). 
While JMY has the ability to enlrance p53-dependent apoptosis, JMYAP, a protein 
isoform o f JMY that arises tlrrough alternative splicing o f the niRNA, has a more 
pronounced effect on p5 3-mediated cell cycle arrest, suggesting that the different 
isoforms o f JMY can modulate the functional outcome o f p53 activation (Shikama 
et al., 1999).
Considering the involvement o f JMY in the p53 response, it was o f interest to 
investigate whether it was regulated by cellular stress. The intracellular 
localisation o f JMY was o f particular interest because previous studies had 
reported variation in the localisation o f the protein, and demonstrated that DNA 
damage results in entranced interaction o f JMY/p300 with the p53 complex 
(Shikama e? £ï/., 1999).
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3-2. The subcellular localisation of JMY in unstressed cells
The subcellular localisation o f JMY was assessed in the absence o f stress. Due to 
difficulty in generating suitable antibodies for the analysis o f endogenous JMY, 
this study focused on the use o f ectopially expressed JMY.
U 20S cells were transfected with the HAJMY expression vector pCMV-HAJMY 
and the subcellular localisation o f HAJMY was examined by indirect 
immunofluorescence (Figure 3.1.A).
To quantify the results, cells were categorised as having exclusively cytoplasmic, 
nuclear, or uniform (both nuclear and cytoplasmic) fluorescence staining and the 
percentage o f cells in each category was graphically represented (Figure 3.1.C).
In U 20S  cells, JMY localised to both the nucleus and the cytoplasm in the 
majority o f cells. A considerable proportion o f transfected cells (42%) also 
displayed exclusively cytoplasmic staining and very few cells (1%) showed 
nuclear staining (Figures 3.1.A and C).
A similar pattern was observed with Flag-tagged JMY and the data were not 
affected by the transfection method nor the amount o f plasmid transfected since 
titration o f the plasmid produced similar results (not shown).
SA 0S2 cells, which lack endogenous p53, were also examined for the 
intracellular distribution o f HAJMY. A similar distribution pattern to that seen in 
U 20S  cells was observed, with the majority o f cells displaying uniform staining
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(73%), and smaller populations exhibiting cytoplasmic and nuclear staining (22% 
and 6%, respectively) (Figures 3 .LB and C).
Interestingly, U 20S  cells appear to contain a relatively higher proportion of 
cytoplasmic-staining cells than SA 0S2 cells (43% and 22 %, respectively), 
suggesting a degree o f cell type variation in the subcellular localisation o f JMY.
3-3. DNA damage causes the translocatioii of JMY into the nucleus
The above experiment showed an important level o f cytoplasmic localisation for 
JMY. JMY cooperates with p300 to stimulate p53-dependent transcription, and 
has been shown to interact more efficiently with p53 under DNA damage 
conditions (Shikama et a/,1999). Considering that DNA damage induces the p53 
response, and that nuclear localisation is required for transcriptional co activation, 
it was speculated that the sub-cellular localisation o f JMY might also be regulated 
by DNA damage.
Tlu'ee types o f DNA damaging treatments, actinomycin D, etoposide and 
exposure to UV, were used to investigate whether JMY was regulated by DNA 
damage. These cause damage to DNA via different mechanisms. Actinomycin D 
blocks the movement o f RNA polymerase along the DNA template by binding 
tightly to DNA whilst UV iiTadiation causes the formation o f pyiimidine dimers, 
and etoposide triggers double strand breaks tlu'ough its ability to target 
topoisomerase II (Friedberg et al., 1995).
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U 20S cells were transfected with pCMV-HAJMY and were treated with 20nM 
actinomycin D for 16 hours, lOpM Etoposide for 7 hours, or exposed to UV (60 
J/m^) and haiwested 6 hours later. Changes in the sub-cellular localisation o f JMY 
compared to untreated control cells were examined by indirect 
immunofluorescence.
Actinomycin D resulted in an almost twofold reduction in the population of cells 
with exclusively cytoplasmic JMY (42% to 24%). This was paralleled by an 
increase in the population o f cells with nuclear JMY (1.7% to 17%). A similar 
effect was observed with UV which caused a shaip decrease in the percentage o f 
cytoplasmic-staining cells (42% to 4.5%) and an increase in cells with nuclear 
(1.7% to 27%), or unifonn (56.4 to 68.5%) staining^ implying translocation of 
the protein into the nucleus (Figures 3.2. A, B, D). In contrast, etoposide 
treatment did not significantly alter the localisation o f JMY (Figures 3.2.C and D). 
Taken together, these data suggest that, under certain conditions o f DNA damage, 
the nuclear localisation o f JMY is eiilianced, possibly by eihianced import or 
reduced nuclear export, which would facilitate its interaction with other 
components o f the p53 complex, and potentially enhance its transcriptional 
coactivation properties.
3-4. Serum withdrawal enhances the cytoplasmic localisation of JMY
The above data show that DNA damaging conditions enlrance the nuclear 
localisation o f JMY. Considering that DNA damage activates cellular 
checkpoints which prevent cell-cycle progression to allow repair o f the damage, it
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was o f interest to examine the subcellular localisation o f JMY under conditions 
which halt cell cycle progression without causing damage to DNA. In particular, 
the effect o f semm deprivation on the intracellular distribution o f JMY was 
examined.
Conditions o f low serum (0.2% serum for 16 hours) did not alter the subcellular 
localisation o f p53 (figure 3.3.A) and, in contrast to actinomycin D treatment, did 
not cause its stabilisation (Figure 3.3.B).
To investigate the response o f JMY to serum withdrawal, U 20S cells were 
transfected with pCMV-HAJMY, and 24 hours following transfection, they were 
incubated for 16 hours in media supplemented with 0.2% serum.
The sub-cellular localisation o f JMY was observed by indirect 
immunofluorescence. Under such conditions, JMY localised exclusively to the 
cytoplasm in the majority o f cells (65%), implying reduced import, or enlianced 
nuclear export o f the protein (Figures 3.3 C, 3.5.B).
Western blot analysis o f HAJMY under these conditions showed the appearance 
o f a faster migrating band following serum withdrawal (Figure 3.3.D, lane 2). 
The possibility that this band is a phospho-form o f the protein was confinned by 
phosphatase treatment of the cell extracts which reduced the appearance of the 
band (Figure 3.3.D lane 3).
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3-5. Rapid cvtpblasmic translocation of JMY in response to serum  ^
withdrawal and nuclear re-entry following serum stimulation
The kinetics o f the cytoplasmic translocation o f JMY in response to serum 
withdrawal were investigated. U 20S  cells were transfected as above and 
incubated in low serum media (0.2% FCS) 24 hours following transcription. The 
subcellular localisation o f JMY was examined following 1, 2, 4 and 16 hours of 
serum withdrawal. At 16 hours, cells were divided into two groups. The first 
group was maintained in low serum media whilst the second gi'oup was incubated 
in 10% FCS media. The subcellular distribution of JMY was examined 4 hours 
later. The data are summarised in figure 3.4.
An increase in the proportion o f cells with cytoplasmic JMY was observed after 
one hour o f serum deprivation (40% to 46%), and this continued tlnoughout the 
time course (Figure 3.4). After 16 hours o f semm withdrawal, approximately 
67% o f cells displayed nuclear exclusion o f JMY. Examination o f the subcellular 
localisation o f JMY after 20 hours revealed a decrease in this population in cells 
stimulated with semm (48%) but not in cells that were maintained in low serum 
(70%) (Figure 3.4).
These data suggest that the cytoplasmic relocalisation o f JMY is an early event 
during semm deprivation, and hint that growth factor signalling may be involved 
in regulating the intracellular distribution o f JMY.
/
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3-6. The cytoplasmic localisation of JMY in serum starved cells is the result 
of nuclear export
The enlianced cytoplasmic localisation o f JMY in semm-stai'ved cells could be the 
outcome o f enhanced nuclear export, or reduced import o f the protein. To 
distinguish between these two events, U 20S cells were transfected with the 
expression vector pCMV-HAJMY, and were subsequently serum starved in the 
presence o f the antibiotic leptomycin B. Leptomycin B is a specific inhibitor of 
nuclear export which targets CRM 1-dependent export and causes the 
accumulation o f CRM 1-substrates in the nucleus (Fomerod et al., 1997; W olff et 
a l,  1997).
Confirming the nuclear export hypothesis, leptomycin B treatment reversed the 
cytoplasmic relocalisation o f HAJMY since there was an increase in the 
percentage o f cells with nuclear HAJMY (7% to 60%), paralleled by a decrease in 
the population o f cells exhibiting cytoplasmic staining (64.5% to 28.5%) 
(compare 3.5.A(i) and (ii) and 3.5.B).
To further confinn that the cytoplasmic localisation o f JMY is the result of active 
transport into the cytoplasm, HAJMY-overexpressing U 20S  cells were incubated 
in 0.2% serum media supplemented with sodium azide. Sodium azide depletes 
the levels o f RanGTP, which is essential for the assembly the nuclear export 
complex (Schwoebel et a l,  2002). Sodium azide treatment reduced the 
cytoplasmic localisation o f JMY (64.5% to 27%) and increased uniform and 
nuclear staining, further demonstrating that NES dependent export is involved in 
JMY regulation (Figures 3.5.A (iii) and 3.5.B).
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3-7. Effect of UV and serum deprivation on the cell cycle function of JMY
JMY has been demonstrated to stimulate both p53-dependent G1 arrest and 
apoptosis (Shikama et al., 1999). Considering that the intracellular distribution o f 
JMY is regulated by DNA damage and serum deprivation, it was o f interest to 
examine the effect o f these conditions on the cell cycle aiTest and apoptotic 
properties o f JMY.
To this end, U 20S cells were transiently transfected with an empty vector, or with 
an expression vector for HAJMY. The cells were exposed to UV, or incubated in 
0.2% FCS media, and the cell cycle profiles were examined and compared to 
profiles o f untreated cells (Figure 3.6).
Overexpression of JMY in unstressed cells caused a two-fold increase in 
apoptosis relative to mock transfected cells (Figure 3.6.A), consistent with the 
ability o f JMY to induce apoptosis in the presence o f p53 (Shikama et al., 1999). 
Surprisingly, a different effect was observed in UV treated cells as a slight 
increase in G1 and decrease in G2/M were observed (Figure 3.6.B). A more 
dramatic effect o f JMY was expected under these conditions due to the UV- 
induced nuclear translocation of JMY. Nevertheless, it camiot be excluded that 
JMY participates to p53-mediated transactivation o f non-apoptotic genes in 
response to UV.
Semm starvation completely abolished the effect o f JMY on the cell cycle and 
the cell cycle profiles are identical in the absence or presence o f overexpressed 
JMY (Figure 3.6.C). This may be explained by the cytoplasmic translocation of
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JMY under these conditions which could prevent it from contributing to 
transcriptional events in the nucleus.
3-8. The proline rich region of JMY is dispensable for response to serum 
withdrawal
The JMY isoform AP, which lacks the proline rich region in the C-tenninus 
(Figure 3.7.A), has distinct properties that distinguish it fiom the wild type 
protein. The two proteins have the ability to augment the p53 response, albeit 
with different outcomes. While wild type JMY preferentially augments apoptosis, 
JMY A? appears to favour p53-dependent cell cycle arrest and is compromised in 
its ability to facilitate apoptosis (Shikama et al., 1999).
To determine whether the different properties o f JMY and JMYAP are reflected in 
their subcellular localisation, HA JMYAP was overexpressed in U 20S  cells and 
changes in its intracellular localisation were assessed in the presence o f DNA 
damage, or following serum staiwation.
Similarly to the wild type protein, the majority o f cells displayed uniform JMYAP 
staining in the absence o f stress. Nevertheless, despite the presence o f HA JMYAP 
in both the nucleus and the cytoplasm, the majority o f these cells exhibited strong 
staining in the nucleus relative to the cytoplasm. In other words, most JMYAP- 
overexpressing cells exhibited strong nuclear and weaker cytoplasmic staining. 
Moreover, the proportion o f cells with exclusive nuclear staining (18%) was 
higher than that obseiwed with the wild type protein (1.6%) (Figures 3.7.B and
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E). These observations suggest that HA JMYAP can more readily localise to the 
nucleus compared to wild type JMY, implying possible differences in the rates o f 
import and/or export between the two iso forms.
W hen JMYAP-overexpressing cells were treated with actinomycin D (20nM for 
16 hours), etoposide (lOpM for 7 hours) or UV (60J/m  ^), there was a very slight 
change in the intracellular localisation o f JMYAP, and no flirther nuclear 
accumulation o f the protein was observed (Figures 3.7. C and E ).
In contrast, serum starvation resulted in an increase in the population o f cells with 
exclusively cytoplasmic JMYAP (18.5% to 61%), paralleled by a decrease in the 
populations with nuclear or unifonn staining (Figures 3.7. D and E). This 
indicates that, in a similar fashion to the wild type protein, JMYAP can be 
exported out o f the nucleus and that its nuclear export is enhanced under 
conditions o f serum starvation.
Given the different responses o f JMY and JMYAP to DNA damage, and the 
ability o f both proteins to undergo nuclear export under low serum conditions, it is 
conceivable that JMY utilises different properties under these conditions and that 
different cellular pathways impinge on the regulation o f JMY.
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3-9. Conclusions
Thi'oiigh its function as a p53 coactivator, JMY is involved in the regulation of 
the p53 response. The data presented here suggest that JMY is itself a regulated 
protein, and that it is regulated at the level of its sub-cellular localisation.
Under normal growth conditions, transfected cells were heterogeneous with 
respect to the localisation of JMY, suggesting that the intracellular distribution of 
JMY might be regulated. Although the majority of cells exhibited both nuclear 
and cytoplasmic localisation, JMY was excluded fi'om the nucleus in a 
considerable proportion of cells, which was not consistent with its function as a 
transcriptional cofactor.
However, DNA damage, as a result of actinomycin D treatment, or exposure to 
UV light, reduced the cytoplasmic localisation of JMY, and caused its 
translocation into the nucleus, the cellular compartment where it is required for 
transcriptional co activation. This is consistent with the entranced ability of JMY 
to interact with p53 and p300 under such conditions, and with its role in 
stimulating p53 activity (Shikama e t a l, 1999). Nevertheless, although it slightly 
enlianced G1 arrest, JMY was unable to augment apoptosis in UV-treated cells. 
It is speculated that nuclear translocation of JMY following UV-treatment might 
regulate its function in processes other than apoptosis.
In contrast to UV and actinomycin D, etoposide treatment did not significantly 
alter the distribution of JMY, suggesting that its relocalisation to the nucleus
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might involve particular cellular signals that are not triggered by etoposide 
treatment.
Furthermore, JMY also responds to signals related to cellular growth. Whereas 
withdrawal of serum did not alter the stability or subcellular distribution of p53, it 
promoted rapid cytoplasmic translocation of JMY which was reversed by serum 
stimulation of starved cells.
The cytoplasmic relocalisation of JMY was blocked by inhibiting CRMl- 
dependent export with leptomycin B, and sodium azide, implicating nuclear 
export in the regulation of the intracellular localisation of JMY.
Moreover, semm deprivation abolished the effect of JMY on the cell cycle, 
suggesting that cytoplasmic relocalisation under these conditions may serve to 
limit the giowth an est or apoptotic functions of JMY.
Besides changes in intracellular localisation, semm starvation resulted in a 
mobility shift of HAJMY which was abrogated by phosphatase treatment, 
suggesting that a phosphorylation event may also be involved in JMY regulation 
under these conditions.
The JMY isofonn JMYAP, which lacks the proline rich region in the C-teiminus, 
displayed stronger nuclear staining relative to the wild type protein. The nuclear 
localisation of JMYAP was not enlianced by actinomycin D, etoposide or UV- 
induced DNA damage, suggesting different mechanisms of regulation for the two
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isofoims. Ill contrast, serum withdrawal augmented the cytoplasmic localisation 
of JMYAP in a similar fashion to the wild type protein.
Taken together, these data indicate that the intracellular distribution of JMY is 
regulated, and may impact on its ability to induce apoptosis or enhance cell cycle 
arrest. Similar mechanisms appear to regulate the localisation of JMY and 
JMYAP in response to serum withdrawal but not in the presence of DNA damage.
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3 ,1 , T h e  su b c e llu la r  lo c a lisa tio n  o f  H A J M Y  in  u n s tre s se d  c e lls
A . U 2 0 S
U20S cells were transfected with 2pg of pCMV-HAJMY. Thirty 
six hours following transfection, the localisation of JMY was 
determined by indirect immunofluorescence using a rabbit anti 
HA antibody (Y-11) and a red fluorescent secondary antibody. 
The nuclear stain DAPI was used to determine the position of 
nuclei.
B , S A 0 S 2
SAOS2 cells were transfected with 3 pg of pCMV-HAJMY and 
fixed 36 hours post-transfection. JMY was detected with the anti- 
HA Y-11 antibody and a red fluorescent secondary antibody.
U20S
B. SAOS2
c. Q u a n tif ic a tio n  o f  th e  in tra c e llu la r  d is tr ib u tio n  o f  
o v e re x p re s se d  J M Y  in  U 2 0 S  a n d  S A O S 2  c e lls :
The data were quantified by scoring 100-150 cells with respect to 
the localisation of JMY. The data represent average values from 3 
separate experiments.
c.
I1  loq 
»  80
%- 60
40
g 20
HAJMY
■ Uniform
□ Cytoplasmic
■ Nuclear
U 20S SAOS2
3 ,2 . T h e  s u b c e llu la r  lo c a lisa tio n  o f  J M Y  in  r e sp o n se  to  D N A  
d a m a s e
A , A c tin o m y c in  D  tr e a tm e n t
U20S ceils were transfected with 2pg pCMV-HAJMY. Twenty 
four hours following transfection, the cells were incubated for 16 
hours in actinomycin D-containing media (20nM) before being 
fixed and examined for the subcellular localisation of JMY. JMY 
was detected with the anti-HA Y-11 antibody and a red fluorescent 
secondary antibody. The nuclear stain DAPI was used to determine 
nuclei position.
B , U V  tr e a tm e n t
U20S cells were transfected with 2pg pCMV-HAJMY. Thirty 
hours following transfection, the cells were exposed to UV (60 
J/mQ for 6 hours. JMY was detected by immunofluorescence 
using the anti-HA Y-11 antibody and a red fluorescent secondaiy 
antibody.
A. Actinomycin D
B. UV
c. E to p o s id e  tr e a tm e n t
U20S cells were transfected with 2pg pCMV-HAJMY. Thirty 
hours following transfection, the cells were treated with 
etoposide (10 pM) for 7 hours. JMY was detected by 
immunofluorescence using the anti-HA Y-11 antibody and a red 
fluorescent secondary antibody. DAPI staining shows the 
position of nuclei.
D , Q u a n tif ic a tio n  o f  th e  e f fe c t  o f  D N A  d a m a g e  o n  J M Y  
lo c a lisa tio n
The data were quantified by scoring 100-150 cells with respect to 
the subcellular localisation of JMY. The data represent average 
values from 3 separate experiments.
c. Etoposide
D.
I^ 100
HAJMY
■ Uniform
□ Cytoplasmic
■ Nuclear
%) 40
control actinomycinD UV etoposide
J.S . T h e  su b c e llu la r  lo c a lisa tio n  o f  J M Y  in  re s p o n s e  to  s e r u m  
w ith d ra w a l
A . T h e su b c e llu la r  lo c a lisa tio n  o f  p S S  is  n o t  a f fe c te d  b y  lo w  
se ru m  c o n d itio n s
Endogenous p53 was visualised in U20S cells that were grown 
under normal growth conditions (i), or following a 16 hour 
incubation in 0.2% serum media (ii). p53 was detected with the 
anti-p53 antibody DO-1 and a green fluorescent secondary 
antibody, and DAPI was used for nuclei identification.
B . S e r u m  s ta rv a tio n  d o e s  n o t  c a u se  th e  a c c u m u la tio n  o f  p 5 3
Endogenous p53 levels in U20S cells were examined under 
normal conditions (lane 1), 16 hours post-treatment with 
actinomycin D (20nM, lane 2), or after 16 hours of serum 
withdrawal (lane 3). Sheep anti-p53 serum was used to detect 
p53.
A.
i)
ii)
B .
Control
0.2% serum
10% ActD 0.2%
p53
C  S e ru m  s ta rv a tio n  c a u se s  th e  tra n s lo c a tio n  o f  J M Y  in to  th e  
c y to p la sm
U20S cells were transfected with 2jag of pCMV-HAJMY and 
incubated in media supplemented with 10% (i) or 0.2%(ii) foetal 
calf serum. JMY was detected by indirect immunofluorescence 
with Y-11 and a red fluorescent secondary antibody.
c. i) 10% serum
H) 0.2% serum
D . J M Y  p h o sp h o ry la tio n  in  r e sp o n se  to  s e r u m  w ith d ra w a l,
HA JMY levels were examined in serum-starved cells. U20S cells 
were transfected with 4|ag pCMV-HA-JMY and were incubated in 
media with 10% serum (lanel), or serum starved (0.2% FCS) for 16 
hours (lanes 2 and 3). Half the cell lysate was used in a 
phosphatase reaction using X phosphatase (lane 3). The arrow 
indicates the position of the faster migrating phosphoform of JMY.
D.
10%_______ 0.2%  0.2%  + phosphatase
JMY
3 .4 . T im e  c o u rse  o f  th e  e f fe c t  o f  s e r u m  d e p r iv a tio n  o n  th e  
s u b c e l l  u la r  lo c a lisa tio n  o f  J M Y
24 hours following transfection with pCMV-HAJMY, U20S cells 
were incubated in 0.2% serum media for 1, 2, 4, and 16 hours. 
After 16 hours, the cells were maintained in low serum media (solid 
lines), or incubated in serum supplemented with 10% FCS (dotted 
lines) for a further 4 hours. The subcellular localisation of JMY 
was examined by indirect immunofluorescence with the anti-HA 
antibody Y-11 and a red fluorescent secondary antibody. The 
graph represents the average of three experiments.
HAJMY
uniform uniform +FCS -A— cytoplasmic -A— cytoplasmic +FCS — nuclear 
10%
FCS
2016420 1
Hours of serum starvation
J.5. R e e u la tio n  o f  th e  lo c a lisa tio n  o f  J M Y  b y  n u c le a r  e x p o r t  
A ,( i)  S e r u m  s ta r v e d  c e lls
Twenty four hours following transfection with 2(ig of pCMV- 
HAJMY, U20S cells were incubated for 16 hours in media with 
0.2% FCS. JMY was detected by immunofluorescence with an 
anti HA antibody (Y-11) and a red fluorescent secondary 
antibody. The position of nuclei was determined using DAPI 
stain.
(ii) L e p to m y c in  B  in h ib its  JM Y ^s c y to p la s m ic  re lo c a lisa tio n
Cells transfected and serum starved as described above. Five 
hours prior to fixation, the nuclear export inhibitor leptomycin B 
was added at a final concentration of 1 pM. JMY was detected 
with the anti-HA Y-11 antibody and a red fluorescent secondary 
antibody.
A.
i) 0.2% serum
0.2% serum+ leptomycin B
(in ). I n h ib itio n  o f  n u c le a r  e x p o r t  w ith  s o d iu m  a z id e  in h ib its  th e  
c y to p la sm ic  re lo c a lisa tio n  o f  J M Y
U20S cells were transfected with 2pg of pCMV-HAJMY and, 24 
hours after transfection, were serum starved for 16 hours. Seven 
hours before fixation, sodium azide was added to the low serum 
media at a final concentration of 10 mM. JMY was detected with 
the anti-HA Y-11 antibody and a red fluorescent secondary 
antibody.
B . Q u a n tif ic a tio n  o f  th e  e f fe c t  o f  le p to m y c in  B  a n d  s o d iu m  a z id e  
o n  th e  lo c a lisa tio n  o f  J M Y  in  se r u m  s ta r v e d  c e lls
The data were quantified by scoring 100-150 cells with respect to 
the subcellular localisation of JMY. The data represent average 
values from 3 separate experiments.
111. 0.2% serum+Azide
B.
^ 0 0
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Control 0.2% serum 0.2% serum+ 0.2%serum+
LeptomycinB Azide
3 ,6 , C e ll  c y c le  e f fe c ts  o f  J M Y  in  re sp o n se  to  U V  a n d  s e r u m  
w ith d ra w a l
A . U20S cells were transfected with Spg of the cell surface 
expression marker CD20 together with 5 pg pcDNA3 empty vector, 
or with 5 pg pCMV-HAJMY. Transfected cells grown in 10% FCS 
were identified by staming with the anti-CD20 fluorescein- 
conjugated antibody and their DNA content observed using the 
DNA inter-chelater propidium iodide. Cell cycle profiles were 
examined with the Cell Quest Pro software.
B . U20S cells were transfected as described in (A). Twenty four 
hours following transfection, cells were incubated in low serum 
media (0.2% FCS) for 16 hours before examination of cell cycle 
profiles with the Cell Quest Pro software.
C. U20S cells were transfected as described in (A). Thirty hours 
post-transfection, cells were exposed to UV (60 J/mQ and were 
incubated for 6 hours prior to cell cycle analysis.
A.
m u J i________ SubGl 12 
G1 35.5 
S 13.5jk
J M X SubGl 24
G1 31
S 13
G2/M 32
B.
Mock
SubGl 13
G2/M 32
JMY
SubGl 13
G2/M 29
c.
Mfl£k SubGl 13
G2/M 31
JMX SubGl 12
G2/M 32
3 .7 , T h e  p r o lin e  r ic h  r e s io n  o f  J M Y  is  n o t  n e c e s sa ry  f o r  n u c le a r  
e x p o r t  in  re sp o n se  to  s e r u m  w ith d ra w a l
A. Schematic representation of JMY and JMY A P
The p300 binding domains (black) and the proline rich region (red) 
are shown. P-rich, proline rich region.
A.
p300 binding I_____ p300 binding P- rich 983
JMY
JMYAP H
983
B . S u b c e llu la r  lo c a lisa tio n  o f  J M Y  A  P  in  u n s tre s se d  c e lls
U20S cells were transfected with 2 \ig  of pCMV- HA-JMY AP. 
JMYAP was detected by indirect immunofluorescence with the 
anti-HA antibody Y-11 and a red fluorescent secondary 
antibody.
C. S u b c e llu la r  lo c a lisa tio n  o f  J M Y  A  P  in  a c tin o m y c in  D  
tr e a te d  c e lls
U20S cells were transfected with 2pg pCMV-HAJMY A P . 
Twenty four hours following transfection, the cells were 
incubated for 16 hours in actinomycin D-containing media 
(20nM) before being fixed and examined for the subcellular 
localisation of JMY. JMY was detected with the anti-HA Y-11 
antibody and a red fluorescent secondary antibody. The nuclear 
stain DAPI was used to determine nuclei position.
B. 10% serum
C.
Actinomycin D
D . S u b c e llu la r  lo c a lisa tio n  o f  J M Y  A  P  s e r u m -s ta r v e d  c e lls
Twenty four hours after transfection with pCMV-HAJMY AP, 
U20S cells were incubated for 16 hours in media supplemented 
with 0.2% foetal calf serum. JMY A P  was detected by indirect 
immunofluorescence with the anti-HA antibody Y-11 mid a red 
fluorescent secondary antibody.
E , Q u a n tif ic a tio n  o f  th e  e f fe c t  o f  s e r u m  starvation^  a n d  D N A  
d a m a g e  o n  th e  su b c e llu la r  lo c a lisa tio n  o f  H A J M Y  A  P
Cells overexpressing HAJMY AP were treated with actinomycin D 
(20nM for 16 hours), UV (60 J/m^and fixed following 6 hours), or 
etoposide (lOpM for 7 hours). The data were quantified by 
scoring 150 cells with respect to the intracellular localisation of 
JMY AP. The data represent average values from 3 separate 
experiments.
D. 0.2% serum
E.
HAJMYAP
■ Uniform
□ Cytoplasmic
■ Nuclear
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Chapter 4. Hdm2 regulates the subcellular localisation of 
JMY
4-1. Introduction
Nuclear localisation is essential for the tumoui* suppressor activity of p53 as 
evidenced by the impaired response to stress signals in certain tumours where 
cytoplasmic sequestration of p53 occurs (Stommel e t a i ,  1999; Moll et 
«/., 1992; 1995). A considerable body of evidence has shown that p53 activity is 
controlled partly by regulation of its localisation within the cell, and the molecular 
mechanisms involved have been intensively studied.
The oncoprotein Mdm2 enhances the cytoplasmic relocalisation of p53. This 
function of Mdm2 is dependent on its ability to interact with p53, and to promote 
its ubiquitination. The importance of Mdm2-directed ubiquitination in p53 export 
is highlighted by studies in which loss of Mdm2-mediated ubiquitination of p53 
blocks p53 export (Boyd e t a l., 2000, Geyer e t a l ,  2000, Lolumn e t a l., 2001).
The data presented in the previous chapter suggest that the subcellular 
distribution of JMY is regulated. Considering that both JMY and p53 are 
regulated at the level of intracellular localisation, and that Mdm2 has nuclear 
export properties, it was of interest to investigate whether Mdm2 could also affect 
the localisation of JMY within the cell.
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4-2. Hdm2 promotes the nuclear export of JMY
To test the hypothesis that Mdm2 regulates the nuclear export of JMY, the effect 
of its co-expression on the intracellular localisation of JMY was assessed.
U20S cells were transfected with the HAJMY expression vector pCMV-HAJMY, 
together with an empty vector, or a plasmid encoding the human homologue of 
Mdm2, Hdm2 (pCHDMIA).
The data were quantified by scoring the cells into tluee categories based on 
whether HAJMY was cytoplasmic, nuclear, or detected in both compartments 
(referred to as unifoim). The majority of cells displayed nuclear Hdni2 and only 
these were included in the study.
In the absence of exogenous Hdm2, HAJMY localised to both the nucleus and the 
cytoplasm, as well as to the cytoplasm in a proportion of cells (Figures 4.1.A(i) 
and 4.1.C). When Hdm2 was co-expressed with HAJMY, an increase in 
cytoplasmic HAJMY (44% to 77%), and decrease in uniform (54% to 23% of 
transfected cells) and nuclear (1.5% to 0% of transfected cells) HAJMY staining 
were observed (Figures 4.1.A (ii) and C).
To determine whether the effect of Hdm2 on HAJMY was the result of nuclear 
export, HAJMY and Hdm2 were co-expressed in the presence of the nuclear 
export inhibitor leptomycin B. Leptomycin B reversed the effect of Hdm2 on 
HAJMY, increasing its nuclear localisation and confiiming that the relocalisation 
of JMY in the presence of elevated levels of Hdm2 involves CRM 1-dependent 
export (Figures 4.1.B, C).
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A possible explanation for the cytoplasmic relocalisation of JMY by Hdni2 is that, 
being part of the p53 complex, JMY is being relocalised as an indirect result of 
Hdm2-med^âted nuclear export of p53.
To test this hypothesis, the effect of Hdm2 on the localisation of HAJMY was 
assessed in the pJJ-null cell line SA0S2. Hdm2 caused the cytoplasmic 
relocalisation of HAJMY in these cells in a similar way to that observed in U20S 
cells, suggesting that p53 is not necessary for JMY relocalisation (Figures 4.1.D 
and E).
4-3. Hdm2 does not mediate the degradation of JMY
In addition to promoting p53 export, Mdm2/Hdm2 also targets it for proteasome- 
dependent degradation (Haupt e t  a l., 1997; Kubbutat e t a l., 1997). Given that 
Hdm2 can enhance the cytoplasmic localisation of JMY, it was of interest to 
determine whether it can also promote its degi'adation in a similar manner to p53.
To this end, U20S cells were transfected with pCMV-HAJMY and an empty 
vector (Figure 4.2. lane 1) or increasing amounts of the Hdm2 expressing 
plasmid pCHDMIA (lanes 2 and 3). The levels of endogenous p53 were 
examined as a positive control.
Hdm2 overexpression did not result in degradation of JMY and JMY levels 
remained stable as opposed to p53 levels, which were efficiently reduced by 
Hdm2 (Figure 4.2). Therefore, Hdm2 does not affect the protein levels of JMY.
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4-4. Effect of Hdm2 on JMY localisation is abolished following DNA 
damage
As UV and actinomycin D-induced DNA damage increased the nuclear 
localisation of JMY, it was of interest to see how Hdm2 could affect the ability of 
JMY to move into the nucleus following DNA damage.
U20S cells over-expressing HAJMY and Hdm2 were treated with actinomycin D 
(20 nM) for 16 hours, or exposed to UV (60J/nf ) and fixed 6 hours later. The 
subcellular localisation of both HAJMY and Hdni2 were examined under these 
conditions and in the absence of stress.
Both treatments attenuated the effect of Hdm2 on HAJMY localisation as 
indicated by the decrease in the percentage of cells exhibiting cytoplasmic 
staining (from 77% in untreated cells to 30% in actinomycin D-treated, and 17% 
in and UV-treated cells), and the increase in uniform and nuclear-staining cells 
compared to untreated cells (Figures 4.3. A-C).
4-5. The proiiue rich region of JMY is necessary for export by Hdm2
The subcellular localisation of JMYAP is regulated in a similar fashion to JMY 
under conditions of serum staiwation, but not in the presence of DNA damage. 
Considering that both isoforms can be regulated by nuclear export, it was 
speculated that Hdm2 could affect the localisation of JMYAP in a similar maimer 
to wild type JMY.
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To examine the effect of Hdm2 on JMYAP, U20S cells were transfected with a 
vector for HAJMYAP expression, pCMV-HAJMYAP, together with an empty 
vector or with the Hdm2 expression vector pCHDMIA. The localisation of 
Hdm2 and HA JMYAP was examined by indirect immunofluorescence as before, 
and cells were scored with respect to the localisation of HAJMYAP.
hi the absence of overexpressed Hdm2, HAJMYAP exhibited both nuclear and 
cytoplasmic staining in the majority of cells, with a lower percentage of cells with 
exclusively cytoplasmic, or nuclear staining (figures 4.4. A(i) and B).
Hdm2 overexpression did not significantly alter this profile, indicating that Hdm2 
fails to relocalise the AP isofomi of JMY (4.4.A (ii) and B).
4-6. Mapping of the functional domains in Hdm2 that are required for 
JMY export
Since the ability of Hdm2 to export p53 requires intact p53 binding and ring 
finger domains (Boyd e t a l., 2000, Geyer e t a l., 2000), it was of interest to assess 
the possibility that these domains are also involved in the cytoplasmic 
relocalisation of JMY.
A panel of Hdm2 mutants with deficient p53-export functions was used to address 
this question (Figure 4.5.A). The Hdm2 mutants 1-440 and C464A have 
deficient ubiquitin ligase domains generated by a deletion, and a single residue 
substitution, respectively. Hdni2 A58-89 contains a deletion in the p53 binding 
domain, and Hdm2 A58-89;C464A, has the same deletion as well as a cysteine to
143
alanine substitution in a zinc coordinating residue in the ubiquitin ligase domain 
(Figure 4.5. A).
The effect of these mutants on the sub-cellular localisation of HAJMY was 
assessed by immunofluorescence in U20S cells (summarised in figure 4.5.F).
In contrast to wild type Hdm2, overexpression of the ring finger mutants Hdm2 
C464A and Hdm2 1-440 did not increase the population of cells with exclusively 
cytoplasmic HAJMY. Interestingly, these mutants allowed the nuclear 
accumulation of HAJMY in a small population of cells (figures 4.5.B, C, F).
The proportion of cells with exclusively cytoplasmic HAJMY increased (44% to 
68%) following overexpression of Hdm2 A58-89 in a similar fashion to wild type 
Hdm2 (figure 4.5.D, F), confirming that p53 is dispensable for Hdm2-driven JMY 
export. However, additional mutation of the ring finger domain in Hdm2 A58-89; 
C464A abolished the cytoplasmic relocalisation of HAJMY as indicated by the 
increase in nuclear and uniform staining of HAJMY, and the decrease in 
cytoplasmic localisation (Figure 4.4.E) relative to Hdm2 A58-89 (27% of 
transfected cells with exclusively cytoplasmic JMY compared to 68% following 
overexpression of Hdm2 A58-89).
Taken together, these results show that, in a similar fashion to p53, an intact ring 
finger is necessary for Hdni2 to promote the cytoplasmic translocation of JMY. 
In contrast, the N-terminal region involved in p53 binding is only required for p53 
export but not for the relocalisation of JMY.
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4-7. Conclusions
The ability of Hdm2 to regulate the intracellular distribution of JMY was 
investigated. The data presented suggest that overexpression of Hdm2 increases 
the cytoplasmic localisation of exogenous JMY in a leptomycin B-sensitive 
mamier suggesting a nuclear export mechanism. This effect of Hdm2 is 
independent of p53 since it was obseiwed in a p53-null context in SAOS2 cells. 
Examination of JMY levels in the presence of elevated levels of Hdm2 indicates 
that, in contrast to p53, Hdm2 does not target JMY for degradation.
Actinomycin D and UY-induced DNA damage was shown to increase the nuclear 
localisation of JMY. This property of JMY is not affected by Hdm2 since Hdm2- 
mediated relocalisation of JMY was compromised under these conditions. This 
suggests that the effect of Hdm2 on JMY is regulated by cellular conditions.
Hdm2 failed to promote the cytoplasmic relocalisation the JMY isoform JMYAP, 
indicating that the C-terminal pro line-rich region of JMY is essential for its 
relocalisation by Hdm2.
Moreover, examination of the domains involved in Hdm2-directed nuclear export 
of JMY revealed the importance of the ring finger of Hdm2. Deletion, or point 
mutation of this domain abrogated its ability to export JMY. In contrast, deletion 
of the p53 binding domain did not affect the ability of Hdm2 to enhance the
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cytoplasmic localisation of JMY, further confinning that p53 is not required for 
this function.
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4.1 . H D M 2  a ffe c ts  th e  su b c e llu la r  lo c a lisa tio n  o f  J M Y
A .( i)  J M Y  in  U 2 0 S  c e lls
U20S cells were transfected with 3pg of pCMV-HAJMY and 
9|uig pcDNA3 empty vector. The subcellular localisation of JMY 
was determined by indirect immunofluorescence 30-36 hours 
post-transfection. JMY was detected with the anti-HA antibody 
Y-11 and a red fluorescent secondary antibody. Nuclei were 
visualised with the nuclear stain DAPI.
(n) H d m 2  e n h a n c e s  th e  c y to p la sm ic  lo c a lisa tio n  of JMY
U20S cells were transfected with 3pg of pCMV-HAJMY and 
9pg of the Hdm2 expression vector pCHDMIA. The subcellular 
localisation of JMY and Hdm2 was determined by indirect 
immunofluorescence 30-36 hours following transfection. JMY 
was detected with the anti-HA antibody (Y-11) and red 
fluorescent secondary antibody. Hdm2 was detected with the 
monoclonal antibody Ab-land a green fluorescent secondary 
antibody. DAPI staining shows the position of nuclei.
A.
(i)
Hdm2 JMY DAPI
(ii)
Hdm2 JMY DAPI
B , L e p to m y c in  B  b lo c k s  th e  re lo c a lisa tio n  o f  J M Y  b y  H d m 2
U20S cells were transfected with 3pg of pCMV-HAJMY and 9p,g 
of the Hdm2 expression vector pCHDMIA, and the subcellular 
localisation of JMY and Hdm2 was determined 36 hours following 
transfection. Five hours prior to fixation, the nuclear export 
inhibitor leptomycinB was added at a final concentration of 1 p,M. 
JMY and Hdm2 were visualised by immunostaining as described in 
(A).
C Q u a n tif ic a tio n  o f  th e  e f fe c t  o f  H d m 2  o n  th e  su b c e llu la r  
lo c a lisa tio n  o f  J M Y
100-150 cells were scored with respect to the subcellular 
localisation of JMY. The data represent average values from 3 
separate experiments. Only cells with nuclear Hdm2 staining 
(which represent the majority of cells) were included.
B.
Hdm2 JMY DAPI
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Hdm2
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D , H d m 2  p r o m o te s  th e  c y to p la sm ic  r e lo c a lisa tio n  o f  J M Y  in  
S A O S 2  c e lls
(i) J M Y  in  S A O S 2  c e lls
SA0S2 cells were transfected with 3jag of pCMV-HAJMY and 
9jag pcDNA3 empty vector. The subcellular localisation of JMY 
was determined by indirect immunofluorescence 30-36 hours post­
transfection. JMY was detected using an anti HA antibody (Y-11) 
and a red fluorescent secondary antibody.
(ii) H d m 2  e n h a n c e s  th e  c y to p la sm ic  lo c a lisa tio n  o f  J M Y  in  
S A O S 2  c e lls
SAOS2 cells were transfected with 3 jag of pCMV-HAJMY and 
9jag of the Hdm2 expression vector pCHDMIA. Thirty six hours 
following transfection, JMY was detected using the polyclonal anti- 
HA antibody Y-11 and a red fluorescin-conjugated antibody. 
Hdm2 was detected with the monoclonal antibody Ab-1 and a 
green fluorescent secondary antibody. DAPI staining shows the 
position of nuclei
D.
(i)
Hdm2 JMY DAPI
(ii)
Hdm2 JMY DAPI
E . Q u a n tif ic a tio n  o f  th e  c y to p la sm ic  re d is tr ib u tio n  o f  J M Y  in  
H d m 2 ~ o ve re x p re ss in g  S A O S 2  c e lls
70“ 100 cells were scored with respect to the subcellular 
localisation of JMY. The data represent average values from 3 
separate experiments and only include data from cells with nuclear 
Hdm2 staining (which represent the majority of cells).
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4.2 . H d m 2  d o e s  n o t  p ro m o te  J M Y  d e g ra d a tio n
U20S cells were transfected with Ijag of pCMV-HAJMY and 
6pg of an empty vector (lane 1), or 3 and 6pg Hdm2 expression 
vector (lanes 2 and 3; respectively). The levels of JMY were 
examined with a mouse anti-HA antibody (HAll). Hdm2 was 
detected with the monoclonal antibody Ab-1. p53 levels were 
examined as a positive control, and p53 was detected with the 
monoclonal antibody DO-1.
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JMY
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4.3 . D N A  d a m a g e  re d u c e s  th e  e f fe c t  o f  H d m 2  o n  th e  s u b c e llu la r  
d is tr ib u tio n  o f  J M Y
A . A c tin o m y c in  D  tr e a tm e n t
U20S cells were transfected with 3 jag of pCMV-HAJMY and 9pg 
of pCHDMIA. Twenty four hours following transfection the cells 
were treated with 20nM actinomycin D for 16hrs.
The subcellular localisation of JMY was visualised by indirect 
immunofluorescence with the anti-HA antibody Y-11 and a red 
fluorescent secondary antibody. Hdm2 was detected with the 
monoclonal antibody Ab-1 and a green fluorescent secondary 
antibody. DAPI staining shows the position of nuclei.
B . U V  tr e a tm e n t
Cells were transfected with 3 and 9jag of pCMV-HAJMY and 
pCHDMIA, respectively. Thirty hours following transfection, cells 
were exposed to UV (60J/m^  ^and fixed 6 hours later. JMY and 
Hdm2 were detected with the Y-11 and Ab-1 antibodies as 
described in (A),
A.
Actinomycin D
Hdm2 JMY DAPI
B.
UV
Hdm2 JMY DAPI
c .  D N A  d a m a g e  re d u c e s  th e  re lo c a lisa tio n  o f  J M Y  b y  H d m 2
70-100 cells were scored with respect to the subcellular localisation 
of JMY. The data represent average values from 3 separate 
experiments. Only cells with nuclear Hdm2 staining (representing 
the majority of cells) were included in the analysis.
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4 .4 , H d m 2  d o e s  n o t  v r o m o te  th e  c y to p la sm ic  tra n s lo c a tio n  o f  
J M Y A P
A  (i). U20S cells were transfected with 3pg of pCMV-HAJMY 
A P  and 9pg pcDNA3 empty vector. The subcellular localisation 
of JMYA P  was determined by indirect immunofluorescence using 
an anti HA antibody (Y-11) and a red fluorescent secondary 
antibody. Nuclei were visualised with the nuclear stain DAPI.
(ii). U20S cells were transfected with 3pg of pCMV-HAJMY A  P  
and 9pg of the Hdm2 expression vector pCHDMIA. The 
subcellular localisation of JMY A  P  was visualised by indirect 
immunofluorescence with the polyclonal anti-HA antibody Y-11 
and a red fluorescent secondary antibody. Hdm2 was detected with 
the monoclonal antibody Ab-1 and a green fluorescent secondary 
antibody, DAPI staining shows the position of nuclei.
A.
(i) Hdm2 JMYAP DAPI
(ii) Hdm2 JMYAP DAPI
B . C o m p a riso n  o f  th e  e f fe c t  o f  H d m 2  o n  th e  s u b c e llu la r  
re lo c a lisa tio n  o f  J M Y  a n d  J M Y A P
100-150 cells were scored with respect to the subcellular 
localisation of JMY and JMY A  P i n  the presence of elevated levels 
of Hdm2. The data represent average values from 3 separate 
experiments.
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4 .5 . M a o v in s  o f  th e  d o m a in s  in  H d m 2  th a t  a re  r e q u ir e d  fo r  J M Y  
e x p o r t
A . D ia g ra m  illu s tra tin g  th e  H d m 2  m u ta n ts  u se d
The p53 binding domain is shown in blue, JMYA58-89 lacks a 
region that is essential for binding to p53. The mutants, 1-440, 
C464A and A58-89;C464A all have deficient ligase activity due to 
ring finger deletion (1-440) or substitution in a critical. Zinc
co-ordinating cysteine (C464A).
A.
HDM2
p53 binding Ring Finger
HDM2 '-49'
491
HDM2 ^58-89
491
HDM2 '-440
I□ 440□
HDM2 C464A Q
491
HDM2 A58-89;C464A [ ~ ^  g
491
B . D e le tio n  o f  th e  r in g  f in g e r  in  H d m 2  1 -4 4 0  a b o lish e s  its  e f fe c t  
on  th e  lo c a lisa tio n  o f  J M Y
U 20S cells were transfected with 3 jag o f pCMV-HAJMY and 6pg 
o f  pCHDM 1-440. The subcellular localisation o f JMY was 
visualised by indirect immunofluorescence with the anti-HA 
antibody Y-11 and a red fluorescent secondary antibody.
Hdm2 1-440 was detected with the monoclonal antibody Ab-1 and 
a green fluorescent secondary antibody. The DAPI staining shows 
the position o f nuclei.
C. H d m 2  C 4 6 4 A  is  u n a b le  to  p r o m o te  th e  n u c le a r  e x p o r t  o f  J M Y
The localisation o f JMY was examined in U 20S  cells transfected 
with the expression vectors pCMV-HAJMY (3pg) and pCHDM 
464 Ala (6pg). Y-11 and a red fluorescent secondary antibody 
were used to detect HAJMY while Hdm2 C464A detection was 
with Ab-1 and a green fluorescent.
B.
C.
1-440 JMY DAPI
C464A JMY DAPI
Z>. H d m 2  A  5 8 -8 9  e n h a n c e s  th e  c y to p la sm ic  lo c a lisa tio n  o f  J M Y
U 20S cells were transfected with 3|rg o f pCMV-HAJMY and 9pg 
o f pCHDM A 58-89. Thiry six hours following transfection, JMY 
was detected with Y-11 and a red fluorescent secondary antibody; 
and Hdm2 A 58-89 was detected with the monoclonal antibody 
Ab-1 and a green fluorescent secondary antibody.
E , M u ta tio n  o f  th e  r in g  f in g e r  in  H d m 2  A  5 8 -8 9  a b o lish e s  th e  
re lo c a lisa tio n  o f  J M Y  in to  th e  c y to p la sm
U 20S cells were transfected with 3jj.g o f pCMV-HAJMY and 6pg 
o f an expression vector for the double mutant Hdm2 A58- 
89;C464A (pCHDM A58-89;C464A). Thiry six hours following 
transfection, JMY was detected with Y-11 and a red fluorescent 
secondary antibody; and Hdm2 A58-89;C464A was detected with 
the monoclonal antibody Ab-1 and a green fluorescent secondary 
antibody.
D .
A58-89 JMY DAPI
E.
A58-89;C464A JMY DAPI
F , Q u a n tif ic a tio n  o f  th e  e f fe c t  o f  H d m 2  m u ta tio n  o n  th e  
s u b c e llu la r  lo c a lisa tio n  o f  J M Y
100-150 cells were scored with respect to the subcellular 
localisation o f JMY. The data represent average values from at 
least 4 separate experiments. Only cells with nuclear Hdm2 
staining (which represent the majority o f cells) were included.
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Chapter 5. Interaction of JMY and Hdm2 in cells
5-1. Introduction
The oncogenic potential o f Mdni2 is largely attributed to its ability to tightly 
regulate the activity o f the p53 tumour suppressor (Momand et al, 2000). 
However, increasing evidence for p53-independent functions o f Hdm2 suggests 
that alternative roles may also contribute to the oncogenic properties o f Hdm2 
(Daujat et a l,  2001).
The list o f Mdm2 interacting partners includes cell cycle regulators such as Rb 
and E2F1 (Martin et al., 1995; Xiao et a l, 1995, Hsieh et a l ,  1999), the tumour 
suppressor PML (Wu et a l ,  2003), ribosomal proteins (Maréchal et a l ,  1994), 
and tissue /or cell type factors such as Numb (Juven-Gershon et a l ,  1998; 
Yogosawa et a l,  2003) and Myo D (Fiddler et a l ,  1996). Nevertheless, the 
physiological significance o f the majority o f these interactions is yet to be 
elucidated, and may point to the involvement o f Mdm2 in the regulation o f cell 
proliferation and /or differentiation.
I have shown above that Hdm2 can affect the intracellular distribution o f JMY in 
the absence o f stress but not under conditions o f DNA damage. This implied the 
existence o f a functional interaction between the two proteins, and prompted the 
analysis o f the physical interaction between JMY and Hdm2 and its potential 
regulation by cellular conditions.
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5-2. JMY and Hdm2 interact in cells
To investigate whether JMY and Hdm2 can fomi a complex, HA-tagged JMY and 
Hdm2 were overexpressed in U 20S  cells, and the cell extracts were 
immuoprecipitated using a monoclonal anti- HA antibody (Figure 5.2.A lane 2), 
or a monoclonal antibody against Mdm2 (Ab-1) (Figure 5.1.A. lane 3). Western 
blot analysis demonstrated the presence o f Hdm2 in JMY immunoprecipitates. 
Endogenous p53 also co-immunoprecipitated with HAJMY, confimiing the 
previous results that JMY associates with the p53 complex (Shikama et a l ,  1999).
The complementary analysis o f immunoprécipitation with an Hdm2 antibody 
showed that, in contrast to endogenous p53, which was efficiently co- 
immunoprecipitated with Hdm2, JMY was not detectable in these 
immunoprecipitates (Figure 5.1.A lane 3, and Figure 5.1.B lane 2). A possible 
explanation is that the Hdm2 antibody Ab-1 interferes with the JMY-Hdm2 
interaction. To test this possibility, the experiment was repeated using the SMP14 
anti- Mdm2 antibody, which recognises a different epitope from Ab-1 (Ab-1 
recognises an epitope between residues 26-150, and the epitope for SMP14 is 
between amino acids 154-167). Both JMY and endogenous p53 were detected in 
the SMP14 Hdm2 immunoprécipitation products (Figure5.1.B. lane 3), but not in 
immunoprecipitates o f an iirelevant antibody (Figure 5.I.B. lane 4) confirming 
the interaction o f JMY and Hdm2 in cells (Figure 5.1 .B. Iane3).
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Further, the interaction o f Hdm2 and the JMY isofonn JMYAP was investigated 
to determine whether the inability o f Hdm2 to translocate JMYAP to the 
cytoplasm reflects lack o f interaction between the two proteins.
HAJMYAP and Hdm2 were overexpressed in U 20S cells and the cell extracts 
were immunoprecipitated with a monoclonal anti-HA antibody, or an iirelevant, 
anti~Gal4 antibody (Figure 5.1.C). Examination o f the HA JMYAP
immunoprecipitates showed the presence o f Hdm2 as well as endogenous p53 
(lane 2) whereas the two proteins were not detected in the control 
immunoprecipitates (lane 3). Therefore, the proline-rich region o f JMY is not 
essential for its ability to interact with Hdm2.
Mutations in the ring finger o f Hdm2 abrogated its ability to promote the nuclear 
export o f JMY whereas deletion o f the p53 binding domains had no effect. To 
test whether these phenotypes are the result o f differential binding to JMY, 
HAJMY was coexpressed with wild type Hdm2, the ring finger mutant C464A or 
the p53 binding mutant A58-89. The interaction was tested by
immunoprécipitation using the anti-Mdni2 antibody SMP14 and the presence of 
endogenous p53 in the immunoprecipitates was examined as a positive control 
(Figure 5.1.D).
p53 efficiently co-immunoprecipitated with both wild type Hdm2 (lane 2) and 
Hdm2 C464A (lane 4) but not with Hdm2 A58-89 (lane 6). A small level of p53 
is detectable in the Hdm2 A58-89 immunoprecipitates which reflects the 
interaction o f p53 with endogenous Hdm2 in U 20S cells (lane 6).
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Examination o f the immunoprécipitation products revealed the ability o f JMY to
interact |Hdm2 A58-89 and Hdm2 C464A as well as with wild type Hdm2. / 
However, the interaction o f JMY with Hdm2 C464A is reduced relative to that 
with wild type Hdm2 and Hdm2 A58-89. This obseiwation may provide a 
potential explanation for the inability of Hdm2 C464A to promote the 
cytoplasmic relocalisation o f JMY.
5-3. The interaction of JMY and Hdm2 is regulated by cellular conditions
The main known function o f Mdm2 is the maintenance o f low levels and activity 
o f p53 under normal conditions. A considerable body o f evidence supports a role 
o f DNA damage in attenuating the inhibition o f p53 by Mdni2, which allows the 
activation o f the tumour suppressor. Several mechanisms have been described 
that intermpt the p53-Mdm2 regulatory loop, including phosphorylation events 
that may interrupt or reduce the interaction between the two proteins, or that 
reduce the ability o f Mdm2 to downregulate p53 without affecting their 
interaction (Inoue et al., 2001; Maya et al., 2001; Alcaron-Vargas and Ronai, 
2002).
Since DNA damage also attenuated Hdm2-mediated redistribution o f JMY, it was 
o f interest to determine the effect of DNA damage on the JMY-Hdm2 interaction.
To this end, Hdm2 and HAJMY were co-expressed in U 20S  cells, which were 
gi’own under normal conditions (Figure 5.2-A), or in the presence o f the DNA 
damaging drug actinomycin D for 16 hours (Figure 5.2.-B). The interaction o f
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HAJMY and Hdm2 was assessed by immunoprécipitation with a monoclonal 
anti-HA antibody (HAl 1) and western blot analysis with the relevant antibodies.
Consistent with the previous results, both Hdm2 and endogenous p53 were co- 
immunoprecipitated with JMY under normal conditions. Actinomycin D caused 
the stabilisation o f p53, which was reflected in its increased levels in the JMY 
immunoprecipitates. However, although Hdm2 was still detected in the 
immunoprecipitates, its levels were reduced by approximately two-fold (reduced 
by 56%) relative to those obseiwed in imstressed cells (compare 5 it.A  lane 2 and 
52 .B  lane 2). This suggests that the JMY-Hdm2 interaction is attenuated by 
actinomycin D treatment, and is consistent with the reduced ability o f Hdm2 to 
stimulate the translocation o f HAJMY into the cytoplasm o f actinomycin D 
treated cells.
Next, the effect of serum starvation on the JMY-Hdm2 interaction was examined. 
HAJMY and Hdm2-progi ammed U 20S  cells were incubated in low serum media 
(0.2%) for 16 hours and the cell extracts were immunoprecipitated as above, using 
a monoclonal anti-HA antibody (Figure 5 ^ C ) .  Under these conditions, neither 
Hdm2 nor endogenous p53 were detected in HAJMY immunoprecipitates. Since 
low serum conditions cause the nuclear exclusion o f JMY, it is conceivable that 
under these conditions, JMY dissociates completely fi'om the p53-Hdm2 
complex.
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5-4. Conclusions
The data presented in this chapter indicate the ability o f JMY and Hdm2 to 
interact in cells. The N-tenninal domain o f Hdm2 might be involved in its ability 
to interact with JMY as suggested by the absence o f interaction in 
immunoprécipitation assays targeting the N-temiinus o f Hdm2. However, the 
ability o f the p53-binding deficient mutant (A58-89) o f Hdni2 to interact with 
JMY indicates that this region is not necessary for the interaction, hiterestingly, 
mutation o f the ubiquitin ligase domain reduces the JMY-Hdm2 interaction, 
which might explain the inability o f this mutant to entrance the cytoplasmic 
localisation o f JMY.
Deletion o f the proline rich region in JMY did not affect its ability to interact with 
Hdm2, indicating that the failure o f JMYAP to undergo Mdm2-mediated export is 
not the result o f lack o f interaction between the proteins. This suggests that the 
interaction with Hdm2 is not sufficient for cytoplasmic relocalisation o f JMY and 
that additional properties o f JMY and/ or additional factors may be involved.
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5,1. J M Y  and H dm 2 interact in cells
A. U 20S  cells were transfected with pCMV-HAJMY(10}rg) and 
pCHDMIA (lOfig), and were harvested 36 hours post-transfection. 
JMY was immunoprecipitated from cell extracts with the mouse 
anti-HA antibody H A l 1 (lane^; and Hdm2 was 
immunoprecipitated with the monoclonal Ab-1 antibody (lane 3). 
JMY was detected with a rabbit anti-HA antibody (Y-11), Hdm2 
witli the polyclonal antibody H-221 and p53 with sheep anti-p53 
serum. The input lane (lane 1) represents 10% o f  the cellular 
extract.
B. U 20S  cells were transfected as described in (A) and the cell 
extracts were subject to immunoprécipitation with the anti-Mdm2 
antibodies Ab-1 (lane 2), or SMP14 (lane 3). Monoclonal anti-Gal4 
antibody was used as a control for specificity (lane 4). JMY was 
detected with a rabbit anti-HA antibody (Y-11), Hdm2 with the 
polyclonal antibody H-221 and p53 with sheep anti-p53 serum, 10% 
o f the extract was loaded as input (lane 1 ).
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C. J M Y  A  P  in te ra c ts  w ith  H d m 2
U 20S cells were transfected with 10 pg o f pCMV-HAJMYAP and 
10 pg pCHDMIA, and harvested 36 hours after transfection. Cell 
extracts were immunoprecipitated with monoclonal anti-HA (lane 
2), or with monoclonal anti-Gal4 antibody (lane 3). The 
immunoprecipitates were analysed for Hdm2 and p53 binding. 
JMY AP was detected with a rabbit anti-HA antibody (Y-11), 
Hdm2 with the polyclonal antibody H-221 and p53 with sheep anti- 
p53 serum. The input lane (lane 1) represents 10% o f  the cellular 
extract.
c.
JMYAP
Hdm2 K
p53
1 2 3
D . J M Y  in te ra c ts  w ith  p 5 3  b in d in s  a n d  r in s  f în s e r  m u ta n ts  o f  
H d m 2
U 20S cells were transfected with 10 pg pCMV-HAJMY and 10
pg o f pCHDMIA (lanes 1 and 2), pC H D M 064A |^ (lanes 3 and 4)A
and pCHDM A58-89 (lanes 5 and 6). Thirty six hours post­
transfection, cell extracts were immunoprecipitated with the anti- 
Mdm2 SMP14 antibody (lanes 2, 4, 6). The immunoprecipitates 
were analysed for the presence o f p53 and HAJMY with sheep 
anti-p53, and rabbit anti JMY (1289) sera, respectively. Hdm2 
was detected with the polyclonal H-221 antibody.
D.
JMY
p53
 IP g  Hdm2_________
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5.2 . T h e  J M Y -H d m 2  in te ra c tio n  is  r e s u la te d  b y  c e llu la r  
co n d itio n s
A . In  u n s tre s se d  c e lls
U 20S cells were transfected with pCMV-HAJMY(10pg) and 
pCHDMIA (lOpg). The cell extracts were immunoprecipitated 
with mouse anti-HA antibody (lane2); or with mouse anti-Gal4 
antibody as a control (lane 3). The immunoprecipitates were 
analysed for Hdm2 and p53 binding. JMY was detected with a 
rabbit anti-HA antibody (Y-11), Hdm2 with the rabbit H-221 
antibody, and p53 with sheep anti-p53 serum. Lane 1 shows the 
input (10% o f cell extract).
B. F o llo w in g  A c tin o m y c in D  tre a tm e n t
U 20S cells were transfected with the pCMV-HAJMY and 
pCHDMIA expression vectors (lOpg o f each). Twenty four hours 
after transfection, cells were incubated in media containing 20 nM 
actinomycin D and were harvested 16 hours later. The lysates were 
immunoprecipitated with an anti-HA antibody (lane 2), or anti- 
Gal4 antibody (lane 3). JMY, p53 and Hdm2 were detected by 
western blot analysis as described in (A).
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c. S e ru m  s ta rv a tio n
Twenty four hours following transfection with pCMV- HAJMY 
(lOpg) and pCHDMIA (lOpg), U 20S  cells were incubated with 
media supplemented with 0.2% foetal calf serum, and harvested 
16 hours later. The presence o f  Hdm2 and p53 in HAJMY 
immunoprecipitates ( lane 2) was examined with the polyclonal 
antibody H-221 for Hdm2 and a sheep serum for p53. HAJMY 
was immunoprecipitated with a mouse anti-HA antibody, and 
detected with the rabbit anti-HA antibody Y-11.
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Chapter 6. Discussion
A multitude o f cellular strategies ensure the tight regulation o f cellular 
proliferation. Defects in the pathways that control the c e l l^  response to DNA 
damage, cell cycle checkpoints or growth stimuli can contribute to inappropriate 
cell division and the initiation, or progression o f cancer.
In addition to control o f protein stability and post-translational modification, 
regulated nuclear transport is proving to be a fundamental and critical mechanism 
in the regulation o f protein function. Regulation o f both nuclear import and 
nuclear export has emerged as an efficient mechanism o f translating signals 
related to the cellular environment into patterns o f gene expression. This control 
mechanism has the advantage o f allowing a rapid response to a particular signal, 
and o f restricting the access o f transcription^'egulators to their target genes in the 
absence o f the appropriate stimulus.
Intensive research in the field of transcriptional regulation yielded multiple 
examples o f the control o f transcription factors by regulated nuclear transport. 
Examples include the cytokine -induced nuclear translocation o f STATs, 
hormone-induced translocation o f ligand—dependent transcription factors, and the 
nuclear export of the p53 tumour suppressor by its negative regulator Mdm2. 
Moreover, the activity o f another class o f transcriptional regulators, caoctivator 
proteins, is increasingly viewed as another layer o f transcriptional control and 
recent studies have highlighted the importance o f nuclear transport in the 
regulation o f some transcriptional cofactors (Muller et a l ,  2002).
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For example, stimulation of Rho signalling induces the translocation of the 
transcriptional coactivator FHL2, which results in the activation o f androgen 
receptor responsive genes (Muller et al., 2002). Moreover, the steroid receptor 
coactivator SRC-2, which is involved in skeletal muscle differentiation, 
translocates into the nucleus during the differentiation process (Chen et al., 2001).
The data presented here relate to the regulation o f the p53 cofactor, JMY. JMY is 
regulated at the level o f subcellular localisation. While conditions o f DNA 
damage entranced the nuclear localisation o f JMY, semm deprivation as well as 
the Mdm2 oncoprotein had the opposite effect, enhancing the relocalisation of 
JMY to the cytoplasm.
6-1. DNA damage enhances the nuclear localisation of JMY
JMY cooperates with p300 to stimulate the p53 response. Conditions o f DNA 
damage entrance the association o f JMY with the p53 complex, indicating that 
stress-depeirdent mechanisms allow the recruitment o f JMY to the p53 complex 
(Shikama et a l ,  1999). The data presented in this thesis suggest that enhancement 
o f the nuclear localisation o f JMY is one such mechanism.
The DNA-damage induced nuclear translocation o f JMY would be predicted to 
facilitate its ability to act as a transcriptional co factor for p53 and to augment p53- 
dependent apoptosis. Examination o f the effect o f UV treatment on the cell cycle 
effect o f JMY revealed that JMY does not augirrent apoptosis under these 
conditions. Considering that the trairscriptional targets o f p53 include genes
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involved in DNA repair and angiogenesis as well as cell cycle arrest and 
apoptosis, it is conceivable that in response to UV, JMY is involved in responses 
other than apoptosis.
The nuclear translocation of JMY was not triggered by all types o f DNA 
damaging treatments. Whilst UV and actinomycin D increased the nuclear 
localisation of JMY, etoposide failed to produce such an effect. A possible 
explanation relates to the type o f damage resulting from each treatment. 
Actinomycin D interacts with DNA, forming obstructive structures for the 
movement o f RNA polymerase, whereas UV promotes the fomiation o f bulky 
adducts within the DNA structure, which would also affect the processivity o f the 
enzyme. Etoposide, in contrast, favours the formation o f double and single strand 
DNA breaks due to its interference with Topoisomerase II (Friedberg et al., 
1995). Therefore, it is conceivable that JMY responds to particular signal 
transduction pathways which are activated upon the formation o f bulky DNA 
structures, or stalled transcription.
Two major components o f the DNA damage checkpoint, ATM and ATR, are 
thought to contribute differentially to the DNA damage checkpoint. ATM has 
been mostly implicated in responses to DNA double strand breaks, whereas ATR 
is thought to regulate responses to various types o f damage, including double 
strand breaks, stalled replication and pyrimidine dimers (Zhou and Elledge, 2000). 
Therefore, it is an attractive, yet unproven speculation that the ATR pathway may 
be involved in enhancing the nuclear localisation o f  JMY. This hypothesis can be
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assessed by overexpression o f a kinase-defective mutant o f ATR, which would be 
predicted to attenuate or abolish the nuclear translocation o f JMY in response to 
UV and actinomycin D.
6-2. Serum deprivation promotes the nuclear export of JMY
In contrast to DNA damage, low serum conditions stimulate the translocation o f 
JMY into the cytoplasm. The effect on subcellular localisation is rapid (obseiwed 
after 1 hour o f semm withdrawal) and is reversed by the réintroduction o f  semm. 
The rapid kinetics o f JMY localisation in response to serum withdrawal, and its 
ability to re-enter the nucleus following serum stimulation suggest a role for 
growth factor signalling in the regulation o f JMY.
Cellular signalling pathways commonly involve signal-regulated translocation of 
proteins between cellular compartments. Phosphorylation is the most frequent 
post-translational modification known to regulate nuclear transport, and a 
considerable number o f examples illustrate the linlc between phosphorylation and 
the subcellular localisation o f signal transduction molecules as well as 
transcription regulators. For example, phosphorylation o f the transcription factor 
NF-AT in the presence o f moderate calcium levels exposes its NES, thus 
enhancing its nuclear export (Tmpin et a i ,  1999). In contrast, phosphorylation of 
p53 has been proposed to block its nuclear export and allow its nuclear 
accumulation in response to DNA damage (Zhang and Xiong, 2001).
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The appearance o f a phosphatase-sensitive, electrophoretically faster migrating 
band o f JMY following serum deprivation suggests that such conditions mediate 
the phosphorylation o f JMY. Although a more common manifestation o f a 
phosphorylation event is a shift to a slower migi'ating form, examples of faster 
electrophoretic mobility have been reported, and include Mdm2 following 
phosphorylation by ATM (Kliosravi et aL, 1999).
It is conceivable that phosphorylation o f JMY triggers its nuclear export or 
impairs its nuclear import, resulting in a predominantly cytoplasmic protein. 
Alternatively, nuclear transport may facilitate the phosphorylation o f JMY in the 
cytoplasm. Identification o f the phosphorylation sites and the kinases involved 
will provide further clues with as to the role o f JMY phosphorylation, and its 
connection with the observed nuclear export.
The relocalisation o f JMY to the cytoplasm occurs via a leptomycin B-, and 
sodium azide-sensitive mechanism. Leptomycin B is an inliihitor o f NES- 
dependent export by CRM l (Fornerod et a l ,  1997; W olff et a l ,  1997) whilst 
sodium azide acts by depleting the levels o f RanGTP, thus disturbing the 
RanGTP/RanGDP giadient across the nuclear membrane. Given that the 
RanGTP/GDP gradient is required for multiple rounds o f  nuclear transport 
(Schwoebel et a l ,  2002), and that sodium azide reduces the nuclear export of 
JMY, these data support the involvement o f the CRM 1 -dependent pathway in 
JMY export, and indicate that it constantly shuttles between the nucleus and the 
cytoplasm.
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Considering that CRM l-dependent nuclear export requires the interaction o f 
CRM l with le u c in ^ ic h  nuclear export sequences (NES), it is likely that JMY 
contains an NES signal. Examination o f the primary protein sequence o f JMY 
reveals the presence o f a leucine-rich sequence which fits the criteria established 
for an NES (Bogerd et al., 1996) (figure 6.1). The importance o f this sequence in 
the nuclear export o f JMY can be assessed by mutation analysis. Moreover, fusion 
o f the minimal sequence to a heterologous, non-shuttling protein would establish 
whether it is sufficient to mediate nuclear export without the assistance o f an 
NES-containing binding partner. O f note, the data presented in this thesis do not 
exclude the possibility that JMY export is mediated by another protein which 
would provide the NES required for nuclear export.
The physiological significance o f the cytoplasmic translocation o f JMY in 
response to serum withdrawal is unclear. It is possible that nuclear export of JMY 
acts to inliibit its activity as a transcriptional cofactor for p53 and that JMY is 
maintained in an inactive state in the cytoplasm. This hypothesis is supported by 
the obseiwation that the ability o f JMY to augment apoptosis is abolished under 
low serum conditions. An alternative and attractive possibility is that JMY 
possesses an additional function in the cytoplasm which is related to serum/ 
growth factor signalling.
Serum signalling also affects actin dynamics, and the absence o f serum 
stimulation is associated with increased levels o f unpolymerised actin (G actin) 
(Miralles et a l,  2003). In this respect, it is intriguing that the C-terminus of JMY
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(residues 916-933) contains a region with high homology to the Wiscott Aldrich 
homology domain (WH2) which has been implicated in actin polymerisation. 
Considering the transcriptional coactivation properties o f JMY and its ability to 
shuttle between the nucleus and the cytoplasm, it would be interesting to examine 
the functional importance o f this domain to assess any potential links between 
transcription and the organisation o f actin. Such a linlc has been demonstrated for 
another transcriptional co factor, MAL, which acts as a transcriptional coactivator 
for the j-erum response Rhetor SRF (Miralles et aL, 2003).
The subcellular localisation o f MAL displays similar dynamics to that o f JMY. 
In serum starved cells, MAL localises predominantly to the cytoplasm due to its 
association with actin monomers. Semm stimulation causes a decrease in the 
levels o f actin monomers, thus allowing the relocalisation o f M AL into the 
nucleus, where it associates with SRF and activates SRE (serum response 
element) mediated gene expression (Miralles et al, 2003).
6-3. Differential regulation of the subcellular localisation of JMY and 
JMYAP
The JMY isoform JMYAP possesses distinct properties hom  the wild type protein 
(Shikama et aL, 1999). JMYAP has been shown to have negligible effects on 
p53-dependent apoptosis, and to augment G1 arrest whereas wild type JMY has a 
more marked effect on apoptosis. At the level o f subcellular localisation, JMYAP 
displays stronger nuclear staining than JMY and, in contrast to JMY, its nuclear 
localisation is not entranced by DNA damage. A possible explanation for the
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observed differences is that nuclear-cytoplasmic shuttling o f JMY may provide an 
additional control mechanism to prevent inappropriate induction o f apoptosis.
Proline-rich domains induce bends in protein structure and have been shown to 
create binding sites for SH3 domains (Yu et aL, 1994). Therefore, it is possible 
that structural differences between JMY and the AP isofomi, and/or potential 
interactions with SH3 containing proteins may influence their association with the 
nuclear transport machinery, and with components o f the damage response.
In contrast, serum withdrawal promotes the relocalisation o f JMYAP to the 
cytoplasm in a similai* fashion to the wild type protein, indicating that the pro line- 
rich region is not essential for the semm response.
Thus, in addition to having different effects on the p53 response, JMY and 
JMYAP are differentially regulated by DNA damaging conditions whereas they 
appear to be regulated in a similar fashion in response to serum withdrawal. 
Taken together, these data imply the possibility that different mechanisms 
regulate JMY in response to DNA damage and to serum withdrawal.
Considering that JMY can constantly shuttle between the nucleus and the 
cytoplasm, and the observed changes in its intracellular distribution under 
different cellular conditions, it is proposed that the steady state distribution of 
JMY is detennined by a balance between import and export mechanisms (figure 
6.2). Depending on the cellular conditions, this balance is shifted by changes in
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the rate o f import, export or both. Thus, DNA damage facilitates nuclear 
accumulation by reducing the rate o f export relative to import. DNA damage has 
been shown to enhance complex fondation between JMY, p300 and p53 (Shikama 
et al., 1999), which could potentially reduce its ability to shuttle to the cytoplasm. 
In contrast, serum starvation increases nuclear export relative to import, thus 
resulting in predominantly cytoplasmic localisation o f JMY.
6-4. Mdm2 affects JMY localisation
The oncoprotein Mdm2 is a major negative regulator o f the p53 tumour 
suppressor, and mediates its inliibitory function partly tluough enliancing the 
nuclear export o f p53.
The data presented here indicate that Mdm2 can also affect the subcellular 
distribution o f the p53 cofactor JMY in a leptomycin B-sensitive, p53- 
independent manner.
The ability o f  Mdm2 to relocalise JMY to the cytoplasm was abrogated following 
treatment with actinomycin D and UV, which are inducers o f DNA damage and 
activators o f p53. This may explain the enhanced nuclear localisation o f JMY 
under these conditions and may be accounted for by modifications affecting JMY, 
Mdni2, or both. Another potential explanation would be that DNA damage 
affects the molecular composition o f the JMY-Mdm2 complex in a way that 
renders JMY resistant to Mdm2- mediated cytoplasmic relocalisation.
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Mdm2-dependent inliibition o f p53 is similarly attenuated under DNA damage 
conditions. For example, ionising radiation-induced Mdm2 phosphorylation 
appears to reduce its ability to promote p53 degradation and export (Maya et a l,  
2001), whereas UV and certain alkylating agents reduce the mRNA and protein 
levels o f Mdm2, allowing the accumulation o f p53 (Inoue et a l ,  2001).
6-5. Mdni2-mediated export of JMY is independent of p53 binding but 
requires an intact ring finger of Mdm2
Mutations that abolish the binding o f Mdm2 to p53 do not reduce its effect on 
JMY sub-cellular distribution. This indicates that Mdm2-mediated relocalisation 
o f JMY is independent o f its ability to bind p53 and is consistent with the fact that 
Mdm2 can promote the redistribution o f JMY into the cytoplasm in the p53-null 
SA 0S2 cells.
In contrast, ring finger domain mutants o f Mdm2 fail to promote the cytoplasmic 
localisation o f JMY, suggesting that the ubiquitin ligase activity o f Mdm2 might 
be involved. Alternatively, mutations in this region might affect the interaction 
between JMY and Mdm2. Interestingly, in a small proportion o f cells, the nuclear 
localisation o f JMY increases in the presence o f these mutants relative to cells 
overexpressing JMY alone. This was also observed in two studies assessing the 
role o f the ring finger domain in Mdm2-dependent export o f p53 (Boyd et a l,  
2000; Geyer et a l ,  2000). These studies used cells that express endogenous 
Mdm2 (NIH 3T3 and U 20S, respectively), and showed the inability o f ring finger
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mutants to relocalise p53 to the cytoplasm. In both studies, the proportion o f cells 
with nuclear p53 was higher in the presence o f the ring finger mutants relative to 
that observed in cells expressing p53 alone. Since U20S/NIH3T3 cells already 
contain endogenous Mdm2, it is conceivable that the ring finger mutants act in a 
dominant negative fashion and inliibit the effect o f  endogenous Mdm2 on JMY, 
and p53. Figure 6.3. summarises the effect o f the described Mdm2 mutations on 
p53 and JMY binding and nuclear export.
Mdm2-mediated export o f JMY might account for the variations in its distribution 
in U 20S  cells, which express endogenous Hdm2, and SA 0S2 cells, which 
express almost undetectable levels o f Hdm2 due to their p53  null status. The 
proportion o f cells displaying nuclear exclusion o f JMY is almost twofold higher 
in U 20S than SA 0S2 cells, which might reflect a degree o f nuclear export by 
endogenous Hdm2 in U 20S cells.
However, a significant percentage o f cells display cytoplasmic JMY staining even 
in SA 0S2 cells and in U 20S  cells in the absence o f overexpressed Mdm2. This 
suggests that additional factors might affect the distribution o f JMY, and that 
Mdm2 enliances the cytoplasmic localisation o f JMY as opposed to being the 
single main regulator o f JMY localisation. Similarly, although Mdm2 can 
significantly enhance p53 export, p53 can shuttle between the nucleus and the 
cytoplasm independently o f Mdm2. For example, an Mdm2-binding defective 
mutant o f p53 has been shown to retain shuttling activity and p53 localisation can 
be regulated by DNA damage independently o f Mdm2 (Stommel et ah, 1999,
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Zhang and Xiong, 2001). The situtation where the subcellular localisation o f a 
protein is regulated by an interacting protein as well as independently o f the 
binding partner is not uncommon. For example, the subcellular localisation o f the 
oncogenic transcription factor (3-catenin is determined by an intrinsic 
nucleocytoplasmic shuttling activity in growth factor stimulated cells. However, 
in the absence o f stimulus, the tumour suppressor AFC actively exports (3- 
catenin into the cytoplasm (Henderson and Fagotto, 2002).
JMYAP is resistant to Mdm2-mediated nuclear export despite maintaining the 
ability to undergo nuclear export in response to serum deprivation. This suggests 
that one or more features associated with the polyproline region o f JMY are 
essential for Mdm2-mediated export. Further, these data indicate that elevated 
levels o f Mdm2 and serum deprivation may utilise different properties o f JMY to 
promote its cytoplasmic relocalisation.
6-6. Mdm2 does not target JMY for degradation
The data presented above suggest that Mdm2 can regulate the subcellular 
localisation o f JMY and p53 by a similar mechanism. However, this similarity 
does not extend to the regulation o f protein levels. In contrast to its ability to 
promote the degi'adation o f p53, Mdm2 fails to downregulate the protein levels o f 
JMY. This might be a reflection o f the fact that JMY is a relatively stable protein 
and does not seem to be regulated at the level o f its stability.
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6-7. JMY and Hdm2 interact in ceils
Consistent with the ability o f Mdm2 to promote the redistribution o f JMY to the 
cytoplasm, the two proteins can interact in cells. However, the ability o f JMYAP 
to interact with Mdm2 indicates that the presence o f JMY and Mdm2 in the same 
complex is not sufficient for Mdm2 to promote the cytoplasmic translocation o f 
JMY, and that an additional property o f JMY that is associated with the proline 
rich region is required.
Accumulating evidence shows that Mdm2 does not always promote both nuclear 
export and degradation o f associated proteins, and complex formation with Mdm2 
does not necessarily translate into reduced levels and nuclear export. For 
example, although it can inhibit p73 function, Mdni2 does not target it for 
degradation nor nuclear export. The inability o f p73 to undergo Mdm2-directed 
nuclear export is attributed to its non-functional nuclear export sequence (Gu et 
a l,  2001).
Another example relates to the regulation o f the E2F/ DP heterodimer (Loughran 
and La Thangue, 2000). Mdm2 dowmegulates the levels o f E2F-1 only in the 
presence o f its heterodimeric partner DP-1, whereas it can promote the 
degradation o f the latter independently o f E2F-1. Moreover, the interaction of 
Mdm2 with DP-1 promotes its nuclear accumulation as opposed to export 
(Loughran and LaThangue, 2000).
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Thus it appears that properties intrinsic to Mdm2“binding proteins detenuine, at 
least in part, the outcome o f the association with Mdm2. This may explain the 
inability o f Mdm2 to promote the degradation o f JMY, and may also account for 
its inability to entrance the nuclear export o f JMYAP.
6-8. Regulation of the JMY-Mdm2 complex by cellular conditions
Examination o f JMY-containing complexes in cells reveals its ability to associate 
with both Mdm2 and p53. The p53-Mdm2-JMY complex seems to possess a 
dynamic nature as it is affected by cellular conditions. Whereas the tliree proteins 
coexist in a complex imder normal conditions, actinomycin D-induced DNA 
damage reduces the ability o f Mdni2 but not p53 to co-immunoprecipitate with 
JMY. This is consistent with the observation that actinomycin D compromises 
Mdm2-mediated nuclear export o f JMY, and might contribute to the nuclear 
accumulation o f JMY in response to actinomycin D.
In contrast, serum staiwation conditions, which stimulate the nuclear export o f 
JMY, not only block the interaction between JMY and Mdm2, but also prevent 
the association o f JMY and p53. A possible explanation is that under these 
conditions, JMY dissociates from the p53 and Mdni2 complex, and is exported 
into the cytoplasm via an M dm2-independent mechanism.
A model for the regulation o f the subcellular localisation o f JMY is proposed 
(figure 6.4). Under normal conditions, JMY constantly shuttles between the 
nucleus and the cytoplasm and can interact with p53 and Mdm2. Mdm2
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enhances the export o f JMY, which presimiably attenuates its function as an 
apoptotic cofactor for p53. DNA damage stimulates the nuclear translocation o f 
JMY and causes a reduction in its association with Mdm2, thus reducing the rate 
o f JMY export and allowing its accumulation in the nucleus. In the nucleus, JMY 
cooperates with p300 to enliance p53-dependent transactivation.
Under conditions o f gi'owth factor/serum deprivation, an Mdm2-independent 
export mechanism is proposed to stimulate the relocalisation o f JMY to the 
cytoplasm and, as a result, JMY dissociates from the p53-Mdm2 complex.
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6-9. Concluding comments:
The results presented in this thesis relate to the regulation o f the p53 co factor 
JMY. JMY is demonstrated to shuttle between the nucleus and the cytoplasm in a 
regulated maimer, and cellular conditions are shown to shift the intracellular 
distribution o f JMY towards a more nuclear or more cytoplasmic localisation. 
The present study focused on the subcellular localisation o f ectopially expressed 
JMY due to difficulty in generating antibodies that are suitable for the analysis o f 
the endogenous protein by immunofluorescence.
In the absence o f serum, a nuclear export mechanism results in a predominantly 
cytoplasmic localisation o f JMY. The opposite effect is produced by certain 
conditions o f DNA damage, which facilitate the recruitment o f JMY to the 
nucleus, the site o f p53 action. Furthermore, the interaction o f JMY and p53 is 
regulated by these conditions. Whereas JMY can associate with p53 in the 
presence o f DNA damage, this interaction is abrogated in the absence o f semm. 
The purification and comparison o f JMY-containing complexes from DNA 
damaged or serum starved cells would provide further insight into the regulation 
of JMY and could potentially reveal other cooperating molecules or targets of 
JMY function.
The finding that the JMY and JMY AP do not respond to DNA damage treatment 
in the same maimer suggests the existence o f divergent regulatory mechanisms for 
the two isofbrms. An intriguing question relates to whether different stress 
signals result in the preferential use o f a particular JMY isoform in the p53
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response. Given the ability o f JMY and JMYAP to modulate the outcome o f the 
p53 activation, further understanding o f their mechanisms o f  regulation could 
provide valuable clues regarding the choice o f the p53 response.
Interestingly, JMY can associate with the p53 inhibitor Mdm2, an interaction 
regulated by cellular conditions. Furthemiore, elevated levels o f Mdm2 result in 
enlianced cytoplasmic localisation o f JMY and this effect is attenuated under 
DNA damage conditions.
The remaining crucial question relates to the functional significance o f  the JMY- 
Mdm2 interaction, and the relocalisation o f JMY by Mdni2. Mdm2-dependent 
inhibition o f p53 occurs at multiple levels, including inhibition o f its interaction 
with transcriptional co activators (Wadgaonkar and Collins, 1999), and recmitment 
o f co-repressors (Mimezami et aL, 2003). It is speculated that Mdm2-mediated 
export o f JMY might represent an additional mechanism o f modulating the 
transcriptional activity o f p53. Since JMY preferentially stimulates p53- 
dependent apoptosis (Shikama et aL, 1999), its cytoplasmic relocalisation in the 
presence o f Mdm2 might serve to attenuate the apoptotic function o f p53. In this 
respect, it would be interesting to compare the effect o f the p53 binding mutant 
(Hdm2 A58-89) and the combined double mutant (Hdm2 A58-89;C464A) on the 
co activation and pro-apoptotic function o f JMY. The above hypothesis predicts 
that Hdm2 A58-89 but not Hdm2 A58-89;C464A (which is deficient in JMY 
export) can reduce or block the effect o f JMY on p53 transcriptional activity and 
apoptosis. Finally, if  the above hypothesis is correct, and if  Mdm2-directed
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export o f JMY attenuates the p53 response, blocking the JMY-Mdni2 interaction 
might stimulate the p53 response, providing potential use in therapy development.
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6.1. P o te n tia l  N E S  se q u e n c e s  o f  J M Y
Sequences in the primary protein sequence o f JMY that fit the 
criteria for an NES are shown. The consensus proposed for an 
NES (Bogerd et aL, 1996) sequence is shown
:S
c/5
Z
I
>■
00 Tf 00m  cN
b  N-j
■ ^  ,  >  I  X
cu Ü  ,
U  >  Ÿ  
Oh >  f S
w a x
W W W
a a ^
C/5 ^
P< U  X  
J ' S  nT
G \ \ 0  (N(N <N
£ws
O'0/%
C/5wz%3%s
%sou
6 .2  M o d e l  fo r  th e  r e g u la tio n  o f  th e  n e t  su b c e llu la r  lo c a lisa tio n  
o f  J M Y
The distribution o f JMY is determined by a balance between 
nuclear import and nuclear export processes. This distribution can 
be altered by shifting the balance towards nuclear import or 
towards export and depends on cellular conditions
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6,4, M o d e l  fo r  th e  r e g u la tio n  o f  th e  s u b c e llu la r  lo c a lisa tio n  o f  J M Y  
b y  M d m 2
A . N o r m a l c o n d itio n s
Under normal conditions, JMY constantly shuttles between the nucleus 
and the cytoplasm and can interact with p53 and Mdm2. Mdm2 
augments the cytoplasmic localisation o f JMY in an NES- dependent, 
leptomycin B-sensitive fashion. This elfect o f Mdm2 is independent 
o f binding to p53 as the p53-binding mutant Hdm2 A58-89 retains the 
ability to associate with and promote the nuclear exclusion o f JMY. In 
contrast, mutation o f the ring finger domain abolishes Mdm2-mediated 
relocalisation o f  JMY, potentially by reducing the ability o f the two 
proteins to interact.
B . D N A  d a m a g e
The association o f Mdm2 with the JMY complex is weakened, thus 
reducing the rate o f  the nuclear export o f  JMY and allowing its 
accumulation in the nucleus, and enhanced interaction with p53.
C. S e ru m  d e p r iv a tio n
Under conditions o f growth factor/serum deprivation, JMY dissociates 
from the p53-Mdm2 complex and is shuttled to the cytoplasm via an 
Mdm2-independent mechanism.
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